USPatent applicationPatented

Combined use of Cry1Ca and Cry1Ab proteins for insect resistance management

Granted 22 Sep 2015 · 2 office actions

Current assignee: Corteva Agriscience · originally DuPont

Law firm: Law firm · Log in to unlock

Attorney: Attorney · Log in to unlock

Inventors: Nicholas P. Storer, Joel J. Sheets, Kenneth Narva, Aaron T. Woosley +2 · Examiner: Anne Kubelik · AU 1662 · TC 1600

Life of the application

12 dated events
⤢ drag to zoom20102012201420162018202020222024202620282030ProsecutionOwnershipTerm & fees
ProsecutionOwnershipTerm & feeshover for detail · click to open

Abstract

The subject invention includes methods and plants for controlling lepidopteran insects, said plants comprising Cry1Ca insecticidal protein and a Cry1Ab insecticidal protein in combination to delay or prevent development of resistance by the insects.

Description

20 parts
›CROSS-REFERENCE TO RELATED APPLICATIONS

This is a national phase application, filed pursuant to 35 U.S.C. §371, of PCT application No. PCT/US10/60819 filed on Dec. 16, 2010, which claims the benefit of U.S. provisional application No. 61/284,292, filed on Dec. 16, 2009. The prior applications are incorporated herein by reference in their entirety.

›BACKGROUND OF THE INVENTION

Humans grow corn for food and energy applications. Humans also grow many other crops, including soybeans and cotton. Insects eat and damage plants and thereby undermine these human efforts. Billions of dollars are spent each year to control insect pests and additional billions are lost to the damage they inflict. Synthetic organic chemical insecticides have been the primary tools used to control insect pests but biological insecticides, such as the insecticidal proteins derived from Bacillus thuringiensis (Bt), have played an important role in some areas. The ability to produce insect-resistant plants through transformation with Bt insecticidal protein genes has revolutionized modern agriculture and heightened the importance and value of insecticidal proteins and their genes.

Several Bt proteins have been used to create the insect-resistant transgenic plants that have been successfully registered and commercialized to date. These include Cry1Ab, Cry1Ac, Cry1Fa and Cry3Bb in corn, Cry1Ac and Cry2Ab in cotton, and Cry3A in potato.

The commercial products expressing these proteins express a single protein except in cases where the combined insecticidal spectrum of 2 proteins is desired (e.g, Cry1Ab and Cry3Bb in corn combined to provide resistance to lepidopteran pests and rootworm, respectively) or where the independent action of the proteins makes them useful as a tool for delaying the development of resistance in susceptible insect populations (e.g., Cry1Ac and Cry2Ab in cotton combined to provide resistance management for tobacco budworm).

That is, some of the qualities of insect-resistant transgenic plants that have led to rapid and widespread adoption of this technology also give rise to the concern that pest populations will develop resistance to the insecticidal proteins produced by these plants.

Several strategies have been suggested for preserving the utility of Bt-based insect resistance traits which include deploying proteins at a high dose in combination with a refuge, and alternation with, or co-deployment of, different toxins (McGaughey et al. (1998), “B.t. Resistance Management,” Nature Biotechnol. 16:144-146).

The proteins selected for use in an insect resistance management (IRM) stack need to exert their insecticidal effect independently so that resistance developed to one protein does not confer resistance to the second protein (i.e., there is not cross resistance to the proteins). If, for example, a pest population selected for resistance to “Protein A” is sensitive to “Protein B”, one would conclude that there is not cross resistance and that a combination of Protein A and Protein B would be effective in delaying resistance to Protein A alone.

In the absence of resistant insect populations, assessments can be made based on other characteristics presumed to be related to mechanism of action and cross-resistance potential. The utility of receptor-mediated binding in identifying insecticidal proteins likely to not exhibit cross resistance has been suggested (van Mellaert et al. 1999). The key predictor of lack of cross resistance inherent in this approach is that the insecticidal proteins do not compete for receptors in a sensitive insect species.

In the event that two B.t. Cry toxins compete for the same receptor, then if that receptor mutates in that insect so that one of the toxins no longer binds to that receptor and thus is no longer insecticidal against the insect, it might also be the case that the insect will also be resistant to the second toxin (which competitively bound to the same receptor). However, if two toxins bind to two different receptors, this could be an indication that the insect would not be simultaneously resistant to those two toxins.

Cry1Ab is an insecticidal protein currently used in transgenic corn to protect plants from a variety of insect pests. A key pest of corn that Cry1Ab provides protection from is the European corn borer.

Additional Cry toxins are listed at the website of the official B.t. nomenclature committee (Crickmore et al.; lifesci.sussex.ac.uk/home/Neil_Crickmore/Bt/). See Appendix A, attached. There are currently nearly 60 main groups of “Cry” toxins (Cry1-Cry59), with additional Cyt toxins and VIP toxins and the like. Many of each numeric group have capital-letter subgroups, and the capital letter subgroups have lower-cased letter sub-subgroups. (Cry1 has A-L, and Cry1A has a-i, for example).

›BRIEF SUMMARY OF THE INVENTION

The subject invention relates in part to the surprising discovery that Cry1Ca is very active against sugarcane borer including a sugarcane borer population that is resistant to Cry1Ab. As one skilled in the art will recognize with the benefit of this disclosure, plants producing Cry1Ca and Cry1Ab (including insecticidal portions thereof), will be useful in delaying or preventing the development of resistance to either of these insecticidal proteins alone. A cry1Fa gene, for example, could also be stacked with these two base pair genes/proteins.

The subject invention also relates to the discovery that Cry1Ca and Cry1Ab do not compete with each other for binding gut receptors from fall armyworm ( Spodoptera frugiperda ; FAW).

›BRIEF DESCRIPTION OF THE FIGURES

FIG. 1-Competition for binding to Spodoptera frugiperda BBMV's by Cry1Ab core toxin, Cry1Ca core toxin, and 125I-labeled Cry1Ca core toxin protein

FIG. 2-Competition for binding to Spodoptera frugiperda BBMV's by Cry1Ca core toxin, Cry1Ab core toxin, and 125I-labeled Cry1Ab core toxin protein.

›BRIEF DESCRIPTION OF THE SEQUENCE

SEQ ID NO:1—Cry1Ca core/Cry1Ab protoxin chimeric protein 1164 aa (DIG-152)

SEQ ID NO:2—a Cry1Ca core toxin

SEQ ID NO:3—a Cry1Ab core toxin

›DETAILED DESCRIPTION OF THE INVENTION · 1 of 6

The subject invention relates in part to the surprising discovery that Cry1Ca is very active against a sugarcane borer (SCB; Diatraea saccharalis ) population that is resistant to Cry1Ab. Accordingly, the subject invention relates in part to the surprising discovery that Cry1Ca can be used in combination with, or “stacked” with, Cry1Ab to combat the development of resistance to either of these insecticidal proteins alone. Stated another way, the subject invention relates in part to the surprising discovery that that a sugarcane borer population selected for resistance to Cry1Ab is not resistant to Cry1Ca; sugarcane borer that are resistant to Cry1Ab toxin are susceptible (i.e., are not cross-resistant) to Cry1Ca. Thus, the subject invention includes the use of Cry1Ca toxin to control populations of sugarcane borer that are resistant to Cry1Ab.

As one skilled in the art will recognize with the benefit of this disclosure, plants expressing Cry1Ca and Cry1Ab (including insecticidal portions thereof), will be useful in delaying or preventing the development of resistance to either of these insecticidal proteins alone.

The subject invention includes the use of Cry1Ca to protect sugarcane and other economically important plant species from damage and yield loss caused by sugarcane borer or to sugarcane borer populations that have developed resistance to Cry1Ab. The sugarcane borer can also be a pest of corn. This is particularly true in some Central and South American countries such as Brazil and Argentina. Thus, corn, for example, can also be protected according to the subject invention.

The subject invention thus teaches an insect resistance management (IRM) stack to prevent or mitigate the development of resistance by sugarcane borer to Cry1Ab and/or Cry1Ca.

In addition, receptor binding studies using radiolabeled Cry1Ca and Spodoptera frugipera ; fall armyworm (FAW) insect tissues show that Cry1Ab does not compete for the high affinity binding site to which Cry1Ca binds. These results indicate that the combination of Cry1Ab and Cry1Ca can be used as an effective means to mitigate the development of resistance in insect populations (such as FAW and SCB) to Cry1Ab and/or Cry1Ca for plants (such as maize and sugarcane) producing both proteins. While toxin overlay studies demonstrated that Cry1Ca protein bound to two proteins in BBMV's from S. frugiperda , one of 40 kDa and one of 44 kDa, whereas Cry1Ab protein bound to a single protein of 150 kDa (Aranda et al., 1996), that did not relate to non-competitive binding studies.

Thus, the subject invention also includes the combination of Cry1Ca and Cry1Ab as an IRM stack to mitigate against the development of resistance by fall armyworm and/or sugarcane borer to either protein, or to sugarcane borer populations that have developed resistance to Cry1Ab.

The present invention provides compositions for controlling lepidopteran pests comprising cells that express a Cry1Ca core toxin-containing protein and a Cry1Ab core toxin-containing protein;

a host transformed to express both a Cry1Ab core toxin-containing protein and a Cry1C core toxin containing protein, wherein said host is a microorganism or a plant cell (the subject polynucleotide(s) are preferably in a genetic construct under control of (operably linked to/comprising) a non- Bacillus - thuringiensis promoter; the subject polynucleotides can comprise codon usage for enhanced expression in a plant);

a method of controlling lepidopteran pests comprising contacting said pests or the environment of said pests with an effective amount of a composition that produces a Cry1Ab core toxin-containing protein and a cell expressing a Cry1C core toxin-containing protein;

a plant (such as a maize plant, or soybeans or cotton or sugarcane, for example) comprising DNA encoding a Cry1Ca core toxin-containing protein and DNA encoding a Cry1Ab core toxin-containing protein, and seed of such a plant;

a plant (such as a maize plant, or soybeans or cotton or sugarcane, for example) wherein DNA encoding a Cry1Ca core toxin-containing protein and DNA encoding a Cry1Ab core toxin-containing protein have been introgressed into said maize plant, and seed of such a plant.

We demonstrated, for example, that Cry1Ca (protein from recombinant Pseudomonas fluorescens strain MR1206/DC639; plasmid pMYC2547) is very effective in controlling sugarcane borer (SCB; Diatraea saccharalis ) populations, in artificial diet bioassays, that have been selected for resistance to Cry1Ab. This indicates that Cry1Ca is useful in controlling SCB populations that have developed resistance to Cry1Ab or in mitigating the development of Cry1Ab resistance in SCB populations.

Based in part on the data described herein, co-expressing Cry1Ca and Cry1Ab can produce a high dose IRM stack for controlling SCB. Other proteins can be added to this combination to add spectrum. For example in corn, the addition of Cry1Fa would create an IRM stack for European corn borer (ECB), Ostrinia nubilalis (Hübner), while adding yet another MOA for control of SCB.

For a review of Cry1C as a potential bioinsecticide in plants, see (Avisar et al. 2009). Avisar D, Eilenberg H, Keller M, Reznik N, Segal M, Sneh B, Zilberstein A (2009) The Bacillus thuringiensis delta-endotoxin Cry1C as a potential bioinsecticide in plants. Plant Science 176:315-324.

Insect Receptors.

As described in the Examples, competitive receptor binding studies using radiolabeled Cry1Ca core toxin protein show that the Cry1Ab core toxin protein does not compete for the high affinity binding site present in FAW insect tissues to which Cry1Ca binds. These results indicate that the combination of Cry1Ab and Cry1Ca proteins would be an effective means to mitigate the development of resistance in FAW populations to Cry1Ab (and likewise, the development of resistance to Cry1Ca), and would likely increase the level of resistance to this pest in corn plants expressing both proteins.

These data also suggest that Cry1Ca would be effective in controlling SCB populations that have developed resistance to Cry1Ab. One deployment option would be to use these Cry proteins in geographies where Cry1Ab has become ineffective in controlling SCB due to the development of resistance. Another deployment option would be to use Cry1Ca in combination with Cry1Ab to mitigate the development of resistance in SCB to Cry1Ab.

›DETAILED DESCRIPTION OF THE INVENTION · 2 of 6

Combinations of the toxins described in the invention can be used to control lepidopteran pests. Adult lepidopterans, i.e., butterflies and moths, primarily feed on flower nectar. The larvae, i.e., caterpillars, nearly all feed on plants, and many are serious pests. Caterpillars feed on or inside foliage or on the roots or stem of a plant, depriving the plant of nutrients and often destroying the plant's physical support structure. Additionally, caterpillars feed on fruit, fabrics, and stored grains and flours, ruining these products for sale or severely diminishing their value. As used herein, reference to lepidopteran pests refers to various life stages of the pest, including larval stages.

The chimeric toxins of the subject invention comprise a full core N-terminal toxin portion of a B.t. toxin and, at some point past the end of the toxin portion, the protein has a transition to a heterologous protoxin sequence. The N-terminal toxin portion of a B.t. toxin is referred to herein as the “core” toxin. The transition to the heterologous protoxin segment can occur at approximately the toxin/protoxin junction or, in the alternative, a portion of the native protoxin (extending past the toxin portion) can be retained with the transition to the heterologous protoxin occurring downstream.

As an example, one chimeric toxin of the subject invention has the full core toxin portion of Cry1Ab (amino acids 1 to 601) and a heterologous protoxin (amino acids 602 to the C-terminus). In one preferred embodiment, the portion of a chimeric toxin comprising the protoxin is derived from a Cry1Ab protein toxin. As a second Example, a second chimeric toxin of the subject invention, as disclosed in SEQ ID NO:1 (DIG-152) has the full core toxin portion of Cry1Ca (amino acids 1 to 619) and a heterologous protoxin (amino acids 620 to the C-terminus). In a preferred embodiment, the portion of a chimeric toxin comprising the protoxin is derived from a Cry1Ab protein toxin.

A person skilled in this art will appreciate that B.t. toxins, even within a certain class such as Cry1Ca, will vary to some extent in length and the precise location of the transition from toxin portion to protoxin portion. Typically, the cry1Ca toxins are about 1150 to about 1200 amino acids in length. The transition from toxin portion to protoxin portion will typically occur at between about 50% to about 60% of the full length toxin. The chimeric toxin of the subject invention will include the full expanse of this core N-terminal toxin portion. Thus, the chimeric toxin will comprise at least about 50% of the full length cry1Ca or Cry1Ab B.t. toxin. This will typically be at least about 590 amino acids. With regard to the protoxin portion, the full expanse of the Cry1A(b) protoxin portion extends from the end of the toxin portion to the C-terminus of the molecule. It is the last about 100 to 150 amino acids of this portion which are most critical to include in the chimeric toxin of the subject invention.

Genes and Toxins.

The genes and toxins useful according to the subject invention include not only the full length sequences disclosed but also fragments of these sequences, variants, mutants, and fusion proteins which retain the characteristic pesticidal activity of the toxins specifically exemplified herein. As used herein, the terms “variants” or “variations” of genes refer to nucleotide sequences which encode the same toxins or which encode equivalent toxins having pesticidal activity. As used herein, the term “equivalent toxins” refers to toxins having the same or essentially the same biological activity against the target pests as the claimed toxins.

As used herein, the boundaries represent approximately 95% (Cry1Ab's and 1Ca's), 78% (Cry1A's and Cry1C's), and 45% (Cry1's) sequence identity, per “Revision of the Nomenclature for the Bacillus thuringiensis Pesticidal Crystal Proteins,” N. Crickmore, D. R. Zeigler, J. Feitelson, E. Schnepf, J. Van Rie, D. Lereclus, J. Baum, and D. H. Dean. Microbiology and Molecular Biology Reviews (1998) Vol 62: 807-813. These cut offs can also be applied to the core toxins only (for Cry1Ab and Cry1C toxins). The GENBANK numbers listed in the attached Appendix A can also be used to obtain the sequences for any of the genes and proteins disclosed or mentioned herein.

It should be apparent to a person skilled in this art that genes encoding active toxins can be identified and obtained through several means. The specific genes or gene portions exemplified herein may be obtained from the isolates deposited at a culture depository as described above. These genes, or portions or variants thereof, may also be constructed synthetically, for example, by use of a gene synthesizer. Variations of genes may be readily constructed using standard techniques for making point mutations. Also, fragments of these genes can be made using commercially available exonucleases or endonucleases according to standard procedures. For example, enzymes such as Bal31 or site-directed mutagenesis can be used to systematically cut off nucleotides from the ends of these genes. Also, genes which encode active fragments may be obtained using a variety of restriction enzymes. Proteases may be used to directly obtain active fragments of these toxins.

Fragments and equivalents which retain the pesticidal activity of the exemplified toxins would be within the scope of the subject invention. Also, because of the redundancy of the genetic code, a variety of different DNA sequences can encode the amino acid sequences disclosed herein. It is well within the skill of a person trained in the art to create these alternative DNA sequences encoding the same, or essentially the same, toxins. These variant DNA sequences are within the scope of the subject invention. As used herein, reference to “essentially the same” sequence refers to sequences which have amino acid substitutions, deletions, additions, or insertions which do not materially affect pesticidal activity. Fragments retaining pesticidal activity are also included in this definition.

›DETAILED DESCRIPTION OF THE INVENTION · 3 of 6

A further method for identifying the gene-encoding toxins and gene portions useful according to the subject invention is through the use of oligonucleotide probes. These probes are detectable nucleotide sequences. These sequences may be detectable by virtue of an appropriate label or may be made inherently fluorescent as described in International Application No. WO93/16094. As is well known in the art, if the probe molecule and nucleic acid sample hybridize by forming a strong bond between the two molecules, it can be reasonably assumed that the probe and sample have substantial homology. Preferably, hybridization is conducted under stringent conditions by techniques well-known in the art, as described, for example, in Keller, G. H., M. M. Manak (1987) DNA Probes, Stockton Press, New York, N.Y., pp. 169-170. Some examples of salt concentrations and temperature combinations are as follows (in order of increasing stringency): 2×SSPE or SSC at room temperature; 1×SSPE or SSC at 42° C.; 0.1×SSPE or SSC at 42° C.; 0.1×SSPE or SSC at 65° C. Detection of the probe provides a means for determining in a known manner whether hybridization has occurred. Such a probe analysis provides a rapid method for identifying toxin-encoding genes of the subject invention. The nucleotide segments which are used as probes according to the invention can be synthesized using DNA synthesizer and standard procedures. These nucleotide sequences can also be used as PCR primers to amplify genes of the subject invention.

Certain toxins of the subject invention have been specifically exemplified herein. Since these toxins are merely exemplary of the toxins of the subject invention, it should be readily apparent that the subject invention comprises variant or equivalent toxins (and nucleotide sequences coding for equivalent toxins) having the same or similar pesticidal activity of the exemplified toxin. Equivalent toxins will have amino acid homology with an exemplified toxin. This amino acid homology will typically be greater than 75%, preferably be greater than 90%, and most preferably be greater than 95%. The amino acid homology will be highest in critical regions of the toxin which account for biological activity or are involved in the determination of three-dimensional configuration which ultimately is responsible for the biological activity. In this regard, certain amino acid substitutions are acceptable and can be expected if these substitutions are in regions which are not critical to activity or are conservative amino acid substitutions which do not affect the three-dimensional configuration of the molecule. For example, amino acids may be placed in the following classes: non-polar, uncharged polar, basic, and acidic. Conservative substitutions whereby an amino acid of one class is replaced with another amino acid of the same type fall within the scope of the subject invention so long as the substitution does not materially alter the biological activity of the compound. Table 1 provides a listing of examples of amino acids belonging to each class.

In some instances, non-conservative substitutions can also be made. The critical factor is that these substitutions must not significantly detract from the biological activity of the toxin.

Recombinant hosts. The genes encoding the toxins of the subject invention can be introduced into a wide variety of microbial or plant hosts. Expression of the toxin gene results, directly or indirectly, in the intracellular production and maintenance of the pesticide. Conjugal transfer and recombinant transfer can be used to create a B.t. strain that expresses both toxins of the subject invention. Other host organisms may also be transformed with one or both of the toxin genes then used to accomplish the synergistic effect. With suitable microbial hosts, e.g., Pseudomonas , the microbes can be applied to the situs of the pest, where they will proliferate and be ingested. The result is control of the pest. Alternatively, the microbe hosting the toxin gene can be treated under conditions that prolong the activity of the toxin and stabilize the cell. The treated cell, which retains the toxic activity, then can be applied to the environment of the target pest.

Where the B.t. toxin gene is introduced via a suitable vector into a microbial host, and said host is applied to the environment in a living state, it is essential that certain host microbes be used. Microorganism hosts are selected which are known to occupy the “phytosphere” (phylloplane, phyllosphere, rhizosphere, and/or rhizoplane) of one or more crops of interest. These microorganisms are selected so as to be capable of successfully competing in the particular environment (crop and other insect habitats) with the wild-type microorganisms, provide for stable maintenance and expression of the gene expressing the polypeptide pesticide, and, desirably, provide for improved protection of the pesticide from environmental degradation and inactivation.

A large number of microorganisms are known to inhabit the phylloplane (the surface of the plant leaves) and/or the rhizosphere (the soil surrounding plant roots) of a wide variety of important crops. These microorganisms include bacteria, algae, and fungi. Of particular interest are microorganisms, such as bacteria, e.g., genera Pseudomonas, Erwinia, Serratia, Klebsiella, Xanthomonas, Streptomyces, Rhizobium, Rhodopseudomonas, Methylophilius, Agrobactenum, Acetobacter, Lactobacillus, Arthrobacter, Azotobacter, Leuconostoc , and Alcaligenes ; fungi, particularly yeast, e.g., genera Saccharomyces, Cryptococcus, Kluyveromyces, Sporobolomyces, Rhodotorula , and Aureobasidium . Of particular interest are such phytosphere bacterial species as Pseudomonas syringae, Pseudomonas fluorescens, Serratia marcescens, Acetobacter xylinum, Agrobactenium tumefaciens, Rhodopseudomonas spheroides, Xanthomonas campestris, Rhizobium melioti, Alcaligenes entrophus , and Azotobacter vinlandii ; and phytosphere yeast species such as Rhodotorula rubra, R. glutinis, R. marina, R. aurantiaca, Cryptococcus albidus, C. diffluens, C. laurentii, Saccharomyces rosei, S. pretoriensis, S. cerevisiae, Sporobolomyces roseus, S. odorus, Kluyveromyces veronae , and Aureobasidium pollulans . Of particular interest are the pigmented microorganisms.

›DETAILED DESCRIPTION OF THE INVENTION · 4 of 6

A wide variety of ways are available for introducing a B.t. gene encoding a toxin into a microorganism host under conditions which allow for stable maintenance and expression of the gene. These methods are well known to those skilled in the art and are described, for example, in U.S. Pat. No. 5,135,867, which is incorporated herein by reference.

Treatment of cells. Bacillus thuringiensis or recombinant cells expressing the B.t. toxins can be treated to prolong the toxin activity and stabilize the cell. The pesticide microcapsule that is formed comprises the B.t. toxin or toxins within a cellular structure that has been stabilized and will protect the toxin when the microcapsule is applied to the environment of the target pest. Suitable host cells may include either prokaryotes or eukaryotes, normally being limited to those cells which do not produce substances toxic to higher organisms, such as mammals. However, organisms which produce substances toxic to higher organisms could be used, where the toxic substances are unstable or the level of application sufficiently low as to avoid any possibility of toxicity to a mammalian host. As hosts, of particular interest will be the prokaryotes and the lower eukaryotes, such as fungi.

The cell will usually be intact and be substantially in the proliferative form when treated, rather than in a spore form, although in some instances spores may be employed.

Treatment of the microbial cell, e.g., a microbe containing the B.t. toxin gene or genes, can be by chemical or physical means, or by a combination of chemical and/or physical means, so long as the technique does not deleteriously affect the properties of the toxin, nor diminish the cellular capability of protecting the toxin. Examples of chemical reagents are halogenating agents, particularly halogens of atomic no. 17-80. More particularly, iodine can be used under mild conditions and for sufficient time to achieve the desired results. Other suitable techniques include treatment with aldehydes, such as glutaraldehyde; anti-infectives, such as zephiran chloride and cetylpyridinium chloride; alcohols, such as isopropyl and ethanol; various histologic fixatives, such as Lugol iodine, Bouin's fixative, various acids and Helly's fixative (See: Humason, Gretchen L., Animal Tissue Techniques, W. H. Freeman and Company, 1967); or a combination of physical (heat) and chemical agents that preserve and prolong the activity of the toxin produced in the cell when the cell is administered to the host environment. Examples of physical means are short wavelength radiation such as gamma-radiation and X-radiation, freezing, UV irradiation, lyophilization, and the like. Methods for treatment of microbial cells are disclosed in U.S. Pat. Nos. 4,695,455 and 4,695,462, which are incorporated herein by reference.

The cells generally will have enhanced structural stability which will enhance resistance to environmental conditions. Where the pesticide is in a proform, the method of cell treatment should be selected so as not to inhibit processing of the proform to the mature form of the pesticide by the target pest pathogen. For example, formaldehyde will crosslink proteins and could inhibit processing of the proform of a polypeptide pesticide. The method of treatment should retain at least a substantial portion of the bio-availability or bioactivity of the toxin.

Characteristics of particular interest in selecting a host cell for purposes of production include ease of introducing the B.t. gene or genes into the host, availability of expression systems, efficiency of expression, stability of the pesticide in the host, and the presence of auxiliary genetic capabilities. Characteristics of interest for use as a pesticide microcapsule include protective qualities for the pesticide, such as thick cell walls, pigmentation, and intracellular packaging or formation of inclusion bodies; survival in aqueous environments; lack of mammalian toxicity; attractiveness to pests for ingestion; ease of killing and fixing without damage to the toxin; and the like. Other considerations include ease of formulation and handling, economics, storage stability, and the like.

Growth of cells. The cellular host containing the B.t. insecticidal gene or genes may be grown in any convenient nutrient medium, where the DNA construct provides a selective advantage, providing for a selective medium so that substantially all or all of the cells retain the B.t. gene. These cells may then be harvested in accordance with conventional ways. Alternatively, the cells can be treated prior to harvesting.

The B.t. cells producing the toxins of the invention can be cultured using standard art media and fermentation techniques. Upon completion of the fermentation cycle the bacteria can be harvested by first separating the B.t. spores and crystals from the fermentation broth by means well known in the art. The recovered B.t. spores and crystals can be formulated into a wettable powder, liquid concentrate, granules or other formulations by the addition of surfactants, dispersants, inert carriers, and other components to facilitate handling and application for particular target pests. These formulations and application procedures are all well known in the art.

Formulations.

Formulated bait granules containing an attractant and spores, crystals, and toxins of the B.t. isolates, or recombinant microbes comprising the genes obtainable from the B.t. isolates disclosed herein, can be applied to the soil. Formulated product can also be applied as a seed-coating or root treatment or total plant treatment at later stages of the crop cycle. Plant and soil treatments of B.t. cells may be employed as wettable powders, granules or dusts, by mixing with various inert materials, such as inorganic minerals (phyllosilicates, carbonates, sulfates, phosphates, and the like) or botanical materials (powdered corncobs, rice hulls, walnut shells, and the like). The formulations may include spreader-sticker adjuvants, stabilizing agents, other pesticidal additives, or surfactants. Liquid formulations may be aqueous-based or non-aqueous and employed as foams, gels, suspensions, emulsifiable concentrates, or the like. The ingredients may include rheological agents, surfactants, emulsifiers, dispersants, or polymers.

›DETAILED DESCRIPTION OF THE INVENTION · 5 of 6

As would be appreciated by a person skilled in the art, the pesticidal concentration will vary widely depending upon the nature of the particular formulation, particularly whether it is a concentrate or to be used directly. The pesticide will be present in at least 1% by weight and may be 100% by weight. The dry formulations will have from about 1-95% by weight of the pesticide while the liquid formulations will generally be from about 1-60% by weight of the solids in the liquid phase. The formulations will generally have from about 10 2 to about 10 4 cells/mg. These formulations will be administered at about 50 mg (liquid or dry) to 1 kg or more per hectare.

The formulations can be applied to the environment of the lepidopteran pest, e.g., foliage or soil, by spraying, dusting, sprinkling, or the like.

Plant Transformation.

A preferred recombinant host for production of the insecticidal proteins of the subject invention is a transformed plant. Genes encoding Bt toxin proteins, as disclosed herein, can be inserted into plant cells using a variety of techniques which are well known in the art. For example, a large number of cloning vectors comprising a replication system in Escherichia coli and a marker that permits selection of the transformed cells are available for preparation for the insertion of foreign genes into higher plants. The vectors comprise, for example, pBR322, pUC series, M13 mp series, pACYC184, inter alia. Accordingly, the DNA fragment having the sequence encoding the Bt toxin protein can be inserted into the vector at a suitable restriction site. The resulting plasmid is used for transformation into E. coli . The E. coli cells are cultivated in a suitable nutrient medium, then harvested and lysed. The plasmid is recovered. Sequence analysis, restriction analysis, electrophoresis, and other biochemical-molecular biological methods are generally carried out as methods of analysis. After each manipulation, the DNA sequence used can be cleaved and joined to the next DNA sequence. Each plasmid sequence can be cloned in the same or other plasmids. Depending on the method of inserting desired genes into the plant, other DNA sequences may be necessary. If, for example, the Ti or Ri plasmid is used for the transformation of the plant cell, then at least the right border, but often the right and the left border of the Ti or Ri plasmid T-DNA, has to be joined as the flanking region of the genes to be inserted. The use of T-DNA for the transformation of plant cells has been intensively researched and sufficiently described in EP 120 516, Lee and Gelvin (2008), Hoekema (1985), Fraley et al., (1986), and An et al., (1985), and is well established in the art.

Once the inserted DNA has been integrated in the plant genome, it is relatively stable. The transformation vector normally contains a selectable marker that confers on the transformed plant cells resistance to a biocide or an antibiotic, such as Bialaphos, Kanamycin, G418, Bleomycin, or Hygromycin, inter alia. The individually employed marker should accordingly permit the selection of transformed cells rather than cells that do not contain the inserted DNA.

A large number of techniques is available for inserting DNA into a plant host cell. Those techniques include transformation with T-DNA using Agrobacterium tumefaciens or Agrobacterium rhizogenes as transformation agent, fusion, injection, biolistics (microparticle bombardment), or electroporation as well as other possible methods. If Agrobacteria are used for the transformation, the DNA to be inserted has to be cloned into special plasmids, namely either into an intermediate vector or into a binary vector. The intermediate vectors can be integrated into the Ti or Ri plasmid by homologous recombination owing to sequences that are homologous to sequences in the T-DNA. The Ti or Ri plasmid also comprises the vir region necessary for the transfer of the T-DNA. Intermediate vectors cannot replicate themselves in Agrobacteria . The intermediate vector can be transferred into Agrobacterium tumefaciens by means of a helper plasmid (conjugation). Binary vectors can replicate themselves both in E. coli and in Agrobacteria . They comprise a selection marker gene and a linker or polylinker which are framed by the Right and Left T-DNA border regions. They can be transformed directly into Agrobacteria (Holsters et al., 1978). The Agrobacterium used as host cell is to comprise a plasmid carrying a vir region. The vir region is necessary for the transfer of the T-DNA into the plant cell. Additional T-DNA may be contained. The bacterium so transformed is used for the transformation of plant cells. Plant explants can advantageously be cultivated with Agrobacterium tumefaciens or Agrobacterium rhizogenes for the transfer of the DNA into the plant cell. Whole plants can then be regenerated from the infected plant material (for example, pieces of leaf, segments of stalk, roots, but also protoplasts or suspension-cultivated cells) in a suitable medium, which may contain antibiotics or biocides for selection. The plants so obtained can then be tested for the presence of the inserted DNA. No special demands are made of the plasmids in the case of injection and electroporation. It is possible to use ordinary plasmids, such as, for example, pUC derivatives.

The transformed cells grow inside the plants in the usual manner. They can form germ cells and transmit the transformed trait(s) to progeny plants. Such plants can be grown in the normal manner and crossed with plants that have the same transformed hereditary factors or other hereditary factors. The resulting hybrid individuals have the corresponding phenotypic properties.

In a preferred embodiment of the subject invention, plants will be transformed with genes wherein the codon usage has been optimized for plants. See, for example, U.S. Pat. No. 5,380,831, which is hereby incorporated by reference. While some truncated toxins are exemplified herein, it is well-known in the Bt art that 130 kDa-type (full-length) toxins have an N-terminal half that is the core toxin, and a C-terminal half that is the protoxin “tail.” Thus, appropriate “tails” can be used with truncated/core toxins of the subject invention. See e.g. U.S. Pat. No. 6,218,188 and U.S. Pat. No. 6,673,990. In addition, methods for creating synthetic Bt genes for use in plants are known in the art (Stewart and Burgin, 2007). One non-limiting example of a preferred transformed plant is a fertile maize plant comprising a plant expressible gene encoding a Cry1Fa protein, and further comprising a second plant expressible gene encoding a Cry1Ca protein.

›DETAILED DESCRIPTION OF THE INVENTION · 6 of 6

Transfer (or introgression) of the Cry1Ab and Cry1C trait(s) into inbred maize lines can be achieved by recurrent selection breeding, for example by backcrossing. In this case, a desired recurrent parent is first crossed to a donor inbred (the non-recurrent parent) that carries the appropriate gene(s) for the Cry1Ab and Cry1C traits. The progeny of this cross is then mated back to the recurrent parent followed by selection in the resultant progeny for the desired trait(s) to be transferred from the non-recurrent parent. After three, preferably four, more preferably five or more generations of backcrosses with the recurrent parent with selection for the desired trait(s), the progeny will be heterozygous for loci controlling the trait(s) being transferred, but will be like the recurrent parent for most or almost all other genes (see, for example, Poehlman & Sleper (1995) Breeding Field Crops, 4th Ed., 172-175; Fehr (1987) Principles of Cultivar Development, Vol. 1: Theory and Technique, 360-376).

Insect Resistance Management (IRM) Strategies.

Roush et al., for example, outlines two-toxin strategies, also called “pyramiding” or “stacking,” for management of insecticidal transgenic crops. (The Royal Society. Phil. Trans. R. Soc. Lond. B . (1998) 353, 1777-1786). On their website, the United States Environmental Protection Agency (epa.gov/oppbppd1/biopesticides/pips/bt_corn_refuge — 2006.htm) publishes the following requirements for providing non-transgenic (i.e., non-B. t.) refuges (a block of non-Bt crops/corn) for use with transgenic crops producing a single Bt protein active against target pests.

The specific structured requirements for corn borer-protected Bt (Cry1Ab or Cry1F) corn products are as follows:

Structured refuges:

20% non-Lepidopteran Bt corn refuge in Corn Belt 50% non-Lepidopteran Bt refuge in Cotton Belt

Blocks

1. Internal (i.e., within the Bt field) 2. External (i.e., separate fields within ½ mile (¼ mile if possible) of the Bt field to maximize random mating)

In-field Strips

Strips must be at least 4 rows wide (preferably 6 rows) to reduce the effects of larval movement

The National Corn Growers Association, on their website (ncga.com/insect-resistance-management-fact-sheet-bt-corn), also provides similar guidance regarding the requirements. For example:

Requirements of the Corn Borer IRM:

Plant at least 20% of your corn acres to refuge hybrids In cotton producing regions, refuge must be 50% Must be planted within ½ mile of the refuge hybrids Refuge can be planted as strips within the Bt field; the refuge strips must be at least 4 rows wide Refuge may be treated with conventional pesticides only if economic thresholds are reached for target insect Bt-based sprayable insecticides cannot be used on the refuge corn Appropriate refuge must be planted on every farm with Bt corn

As stated by Roush et al. (on pages 1780 and 1784 right column, for example), stacking or pyramiding of two different proteins each effective against the target pests and with little or no cross-resistance can allow for use of a smaller refuge. Roush suggests that for a successful stack, a refuge size of less than 10% refuge, can provide comparable resistance management to about 50% refuge for a single (non-pyramided) trait. For currently available pyramided Bt corn products, the U.S. Environmental Protection Agency requires significantly less (generally 5%) structured refuge of non-Bt corn be planted than for single trait products (generally 20%).

Any of the above percentages (such as those for 1F/1Ab), or similar refuge ratios, can be used for the subject double or triple stacks or pyramids. The subject invention includes commercial acreage—of over 10 acres for example—planted with (or without) such refuge and with plants according to the subject invention.

There are various ways of providing the refuge, including various geometric planting patterns in the fields (as mentioned above), to in-bag seed mixtures, as discussed further by Roush and, for example, U.S. Pat. No. 6,551,962.

All patents, patent applications, provisional applications, and publications referred to or cited herein are incorporated by reference in their entirety to the extent they are not inconsistent with the explicit teachings of this specification. Unless specifically indicated or implied, the terms “a”, “an”, and “the” signify “at least one” as used herein.

The following examples illustrate the invention. The examples should not be construed as limiting.

›Examples8
›Example 1 · 1 of 2

Design of Chimeric Toxins Comprising Cry1 Core Toxins and Heterologous Protoxins, and Insecticidal Activity of Dig-152 Protein Produced in Pseudomonas fluorescens

Chimeric Toxins.

Chimeric proteins utilizing the core toxin domain of one Cry toxin fused to the protoxin segment of another Cry toxin have previously been reported, for example, in U.S. Pat. No. 5,593,881 and U.S. Pat. No. 5,932,209.

Cry1Ca chimeric protein variants of this invention include chimeric toxins comprising an N-terminal core toxin segment derived from a Cry1Ca3 insecticidal toxin fused to a heterologous delta endotoxin protoxin segment at some point past the end of the core toxin segment. The transition from the core toxin to the heterologous protoxin segment can occur at approximately the native core toxin/protoxin junction, or a portion of the native protoxin (extending past the core toxin segment) can be retained, with the transition to the heterologous protoxin occurring downstream. In variant fashion, the core toxin and protoxin segments may comprise exactly the amino acid sequence of the native toxins from which they are derived, or may include amino acid additions, deletions, or substitutions that do not diminish, and may enhance, the biological function of the segments when fused to one another.

For example, a chimeric toxin of the subject invention comprises a core toxin segment derived from Cry1Ca3 and a heterologous protoxin. In a preferred embodiment of the invention, the core toxin segment derived from Cry1Ca3 (619 amino acids) is fused to a heterologous segment comprising a protoxin segment derived from a Cry1Ab delta-endotoxin (545 amino acids). The 1164 amino acid sequence of the chimeric protein, herein referred to as DIG-152, is disclosed as SEQ ID NO:1. It is to be understood that other chimeric fusions comprising Cry1Ca3 core toxin variants and protoxins derived from Cry1Ab are within the scope of this invention.

Lepidopteran insecticidal activity of the DIG-152 protein was demonstrated on neonate larvae of sugarcane borer (SCB; Diatraea saccharalis ) and Cry1Ab-resistant SCB (rSCB) in dose-response experiments utilizing diet incorporation procedures. DIG-152 inclusion bodies were solubilized by rocking gently at 4° for 4 hrs in 7.5 mL of 100 mM CAPS pH11, 1 mM EDTA, to which had been added 200 μL of bacterial protease inhibitor (Sigma P4865; prepared per supplier's instructions). Following centrifugation to pellet the insoluble material, the stock protein concentration was adjusted to 4.0 mg/mL in 100 mM CAPS, pH11. For insect bioassay, DIG-152 protein concentrations in the range of 0.030 μg to 102 μg/gm diet were prepared by mixing appropriate volumes with a meridic diet (Bio-Serv, Frenchtown, N.J.) just prior to dispensing approximately 0.7 mL of the diet into individual cells of 128-cell trays (Bio-Ba-128, C-D International).

Trypsin-activated Cry1Ab protein (used as a positive control for insecticidal activity) was tested in the range of 0.03125 μg to 32 μg/gm diet (prepared by mixing lyophilized powder with appropriate amounts of distilled water before diet preparation).

Diets prepared with distilled water (Blank Control, for Cry1Ab tests) or Buffer Only (100 mM CAPS pH11, for DIG-152 tests) were used as control treatments. One neonate larva of D. saccharalis (<24 hr after eclosion) was released on the diet surface in each cell. After larval inoculation, cells were covered with vented lids (C-D International) and the bioassay trays were placed in an environmental chamber maintained at 28°, 50% RH, and a 16 hr:8 hr (light:dark) photoperiod. Larval mortality, larval weight, and number of surviving larvae that did not demonstrate weight gains (<0.1 mg per larva) were recorded on the seventh day after inoculation. Each combination of insect strain/Cry protein concentration was replicated four times, with 16 to 32 larvae in each replicate.

Larval mortality criteria were measured as “practical” mortality, which considered both the Dead (morbid) larvae and the surviving (Stunted, non-feeding) larvae that did not show a significant gain in body weight (i.e. <0.1 mg per larva). The practical mortality of larvae in a treatment was calculated using the equation:

Practical Mortality(%)=[TDS/TNIT]×100

where TDS is the Total number of Dead larvae plus the number of Stunted larvae, and TNIT is the Total Number of Insects in the Treatment

The “practical” mortality (hereafter simplified as Mortality) of each D. saccharalis strain was corrected for larval mortality observed on water Blank Control diet for analyzing results following Cry1Ab treatment, or the Buffer Only-treated diet for the DIG-152 treatment.

The results of the dose response experiments were further analyzed to establish a GI 50 value, [i.e. the concentration of B.t. protein in the diet at which the larval growth inhibition (% GI) value was 50]. The % GI value of larvae on diet containing Cry1Ab-protein was calculated using the formula:

% GI=[TWC−TWT]/TWC×100

where TWC is the Total body Weight of larvae feeding on water Control diet, and TWT is the Total body Weight of larvae feeding on Cry1Ab Treated diet

whereas, for analyzing larval % GI as a result of DIG-152 protein ingestion, it was calculated using the formula:

% GI=[TWB−TWT]/TWB×100

where TWB is the Total body Weight of larvae feeding on Buffer-Only control treated diet, and TWT is the Total body Weight of larvae feeding on DIG-152 Treated diet

A larval growth inhibition of 100% was assigned to a replication if there were no larvae that had significant weight gain (<0.1 mg per larva). The growth inhibition data were analyzed using a two-way ANOVA with insect strain and Cry protein concentration as the two main factors. LSMEANS tests were used to determine treatment differences at the α=0.05 level.

The results of the diet-incorporation bioassays on Diatraea saccharalis larvae are given in Table 2.

Data Analysis.

Corrected dose/mortality data then were subjected to probit analysis for determining treatment protein concentrations that caused a 50% mortality (LC 50 ) value and the corresponding 95% confidence intervals (CI). The treatments used in the probit analysis included the highest concentration that produced zero mortality, the lowest concentration that resulted in 100% mortality, and all results between those extremes. Resistance ratios were calculated by dividing the LC 50 value of the rSCB strain by that of the SCB insects. A lethal dose ratio test was used to determine if the resistance ratios were significant at α=0.05 level. A two-way ANOVA also was used to analyze the mortality data, followed by the LSMEANS test at the α=0.05 level to determine treatment differences. The results of the analyses are presented in Table 3.

›Example 1 · 2 of 2

It is a feature of the DIG-152 protein of the subject invention that the growth of neonate sugarcane borer ( Diatraea saccharalis ) larvae is inhibited, or the larvae are killed, following ingestion of DIG-152 protein at levels similar to those of activated Cry1Ab protein which give the same biological response. It is a further feature of the DIG-152 protein that Diatraea saccharalis larvae that are resistant to the toxic effects of Cry1Ab protein are nonetheless susceptible to the toxic action of the DIG-152 protein.

›Example 2 · 1 of 2

Construction of Expression Plasmids Encoding Chimeric Proteins and Expression in Pseudomonas

Standard cloning methods [as described in, for example, Sambrook et al., (1989) and Ausubel et al., (1995), and updates thereof] were used in the construction of Pseudomonas fluorescens (Pf) expression construct pMYC2547 engineered to produce a full-length DIG-152 chimeric protein. Protein production was performed in Pseudomonas fluorescens strain MB214 (a derivative of strain MB101; P. fluorescens biovar I), having an insertion of a modified lac operon as disclosed in U.S. Pat. No. 5,169,760. The basic cloning strategy entailed subcloning a DNA fragment encoding DIG-152 into plasmid vectors, whereby it is placed under the expression control of the Ptac promoter and the rrnBT1T2 terminator from plasmid pKK223-3 (PL Pharmacia, Milwaukee, Wis.). One such plasmid was named pMYC2547, and the MB214 isolate harboring this plasmid is named Dpf108.

Growth and Expression Analysis in Shake Flasks

Production of DIG-152 protein for characterization and insect bioassay was accomplished by shake-flask-grown P. fluorescens strain Dpf108. DIG-152 protein production driven by the Ptac promoter was conducted as described previously in U.S. Pat. No. 5,527,883. Details of the microbiological manipulations are available in Squires et al., (2004), US Patent Application 20060008877, US Patent Application 20080193974, and US Patent Application 20080058262, incorporated herein by reference. Expression was induced by addition of isopropyl-β-D-1-thiogalactopyranoside (IPTG) after an initial incubation of 24 hours at 30° with shaking Cultures were sampled at the time of induction and at various times post-induction. Cell density was measured by optical density at 600 nm (OD 600 ).

Cell Fractionation and SDS-PAGE Analysis of Shake Flask Samples

At each sampling time, the cell density of samples was adjusted to OD 600 =20 and 1 mL aliquots were centrifuged at 14000×g for five minutes. The cell pellets were frozen at −80°. Soluble and insoluble fractions from frozen shake flask cell pellet samples were generated using EasyLyse™ Bacterial Protein Extraction Solution (EPICENTRE® Biotechnologies, Madison, Wis.). Each cell pellet was resuspended in 1 mL EasyLyse™ solution and further diluted 1:4 in lysis buffer and incubated with shaking at room temperature for 30 minutes. The lysate was centrifuged at 14,000 rpm for 20 minutes at 4° and the supernatant was recovered as the soluble fraction. The pellet (insoluble fraction) was then resuspended in an equal volume of phosphate buffered saline (PBS; 11.9 mM Na 2 HPO 4 , 137 mM NaCl, 2.7 mM KCl, pH7.4).

Samples were mixed 1:1 with 2× Laemmli sample buffer containing β-mercaptoethanol (Sambrook et al., supra.) and boiled for 5 minutes prior to loading onto Criterion XT Bis-Tris 12% gels (Bio-Rad Inc., Hercules, Calif.). Electrophoresis was performed in the recommended XT MOPS buffer. Gels were stained with Bio-Safe Coomassie Stain according to the manufacturer's (Bio-Rad) protocol and imaged using the Alpha Innotech Imaging system (San Leandro, Calif.).

Inclusion Body Preparation.

DIG-152 protein inclusion body (IB) preparations were performed on cells from P. fluorescens fermentations that produced insoluble Bt insecticidal protein, as demonstrated by SDS-PAGE and MALDI-MS (Matrix Assisted Laser Desorption/Ionization Mass Spectrometry). P. fluorescens fermentation pellets were thawed in a 37° water bath. The cells were resuspended to 25% w/v in lysis buffer [50 mM Tris, pH 7.5, 200 mM NaCl, 20 mM EDTA disodium salt (Ethylenediaminetetraacetic acid), 1% Triton X-100, and 5 mM Dithiothreitol (DTT); 5 mL/L of bacterial protease inhibitor cocktail (Catalog #P8465; Sigma-Aldrich, St. Louis, Mo.) were added just prior to use]. The cells were suspended using a hand-held homogenizer at lowest setting (Tissue Tearor, BioSpec Products, Inc., Bartlesville, Okla.). Lysozyme (25 mg of Sigma L7651, from chicken egg white) was added to the cell suspension by mixing with a metal spatula, and the suspension was incubated at room temperature for one hour. The suspension was cooled on ice for 15 minutes, then sonicated using a Branson Sonifier 250 (two 1-minute sessions, at 50% duty cycle, 30% output). Cell lysis was checked by microscopy. An additional 25 mg of lysozyme were added if necessary, and the incubation and sonication were repeated. Following confirmation of cell lysis via microscopy, the lysate was centrifuged at 11,500×g for 25 minutes (4°) to form the IB pellet, and the supernatant was discarded. The IB pellet was resuspended with 100 mL lysis buffer, homogenized with the hand-held mixer and centrifuged as above. The IB pellet was repeatedly washed by resuspension (in 50 mL lysis buffer), homogenization, sonication, and centrifugation until the supernatant became colorless and the IB pellet became firm and off-white in color. For the final wash, the IB pellet was resuspended in sterile-filtered (0.22 μm) distilled water containing 2 mM EDTA, and centrifuged. The final pellet was resuspended in sterile-filtered distilled water containing 2 mM EDTA, and stored in 1 mL aliquots at −80°.

SDS-PAGE analysis and quantitation of protein in IB preparations was done by thawing a 1 mL aliquot of IB pellet and diluting 1:20 with sterile-filtered distilled water. The diluted sample was then boiled with 4× reducing sample buffer [250 mM Tris, pH6.8, 40% glycerol (v/v), 0.4% Bromophenol Blue (w/v), 8% SDS (w/v) and 8% β-mercaptoethanol (v/v)] and loaded onto a Novex® 4-20% Tris-Glycine, 12+2 well gel (Invitrogen) run with 1× Tris/Glycine/SDS buffer (BioRad). The gel was run for 60 min at 200 volts then stained with Coomassie Blue (50% G-250/50% R-250 in 45% methanol, 10% acetic acid), and destained with 7% acetic acid, 5% methanol in distilled water. Quantification of target bands was done by comparing densitometric values for the bands against Bovine Serum Albumin (BSA) standard samples run on the same gel to generate a standard curve.

›Example 2 · 2 of 2

Solubilization of Inclusion Bodies.

Six mL of DIG-152 inclusion body suspension from Pf clone DPf108 were centrifuged on the highest setting of an Eppendorf model 5415C microfuge (approximately 14,000×g) to pellet the inclusions. The storage buffer supernatant was removed and replaced with 25 mL of 100 mM sodium carbonate buffer, pH11, in a 50 mL conical tube. Inclusions were resuspended using a pipette and vortexed to mix thoroughly. The tube was placed on a gently rocking platform at 4° overnight to extract the target protein. The extract was centrifuged at 30,000×g for 30 min at 4°, and the resulting supernatant was concentrated 5-fold using an Amicon Ultra-15 regenerated cellulose centrifugal filter device (30,000 Molecular Weight Cutoff; Millipore). The sample buffer was then changed to 10 mM CAPS [3-(cyclohexamino)1-propanesulfonic acid] pH 10 using disposable PD-10 columns (GE Healthcare, Piscataway, N.J.).

Solubilization and Trypsin Activation of Inclusion Body Protein.

In some instances, DIG-152 inclusion body suspension from Pf clone DPf108 was centrifuged on the highest setting of an Eppendorf model 5415C microfuge (approximately 14,000×g) to pellet the inclusions. The storage buffer supernatant was removed and replaced with 100 mM CAPS, pH 11 to provide a protein concentration of approximately 50 mg/mL. The tube was rocked at room temperature for three hours to completely solubilize the protein. Trypsin was added at an amount equal to 5% to 10% (w:w, based on the initial weight of IB powder) and digestion was accomplished by incubation while rocking overnight at 4° or by rocking 90-120 minutes at room temperature. Insoluble material was removed by centrifugation at 10,000×g for 15 minutes, and the supernatant was applied to a MonoQ anion exchange column (10 mm by 10 cm). Activated DIG-152 protein was eluted (as determined by SDS-PAGE, see below) by a 0% to 100% 1 M NaCl gradient over 25 column volumes. Fractions containing the activated protein were pooled and, when necessary, concentrated to less than 10 mL using an Amicon Ultra-15 regenerated cellulose centrifugal filter device as above. The material was then passed through a Superdex 200 column (16 mm by 60 cm) in buffer containing 100 mM NaCl. 10% glycerol, 0.5% Tween-20 and 1 mM EDTA. It was determined by SDS-PAGE analysis that the activated (enzymatically truncated) protein elutes at 65 to 70 mL. Fractions containing the activated protein were pooled and concentrated using the centrifugal concentrator as above.

Gel Electrophoresis.

The concentrated protein preparations were prepared for electrophoresis by diluting 1:50 in NuPAGE® LDS sample buffer (Invitrogen) containing 5 mM DTT as a reducing agent and heated at 95° for 4 minutes. The sample was loaded in duplicate lanes of a 4-12% NuPAGE® gel alongside five BSA standards ranging from 0.2 μg to 2 μg/lane (for standard curve generation). Voltage was applied at 200 V using MOPS SDS running buffer (Invitrogen) until the tracking dye reached the bottom of the gel. The gel was stained with 0.2% Coomassie Blue G-250 in 45% methanol, 10% acetic acid, and destained, first briefly with 45% methanol, 10% acetic acid, and then at length with 7% acetic acid, 5% methanol until the background cleared. Following destaining, the gel was scanned with a BioRad Fluor-S MultiImager. The instrument's Quantity One Software v.4.5.2 was used to obtain background-subtracted volumes of the stained protein bands and to generate the BSA standard curve that was used to calculate the concentration of chimeric DIG-152 protein in the stock solution.

›Example 3

Preparation of Cry1Ca and Cry1Ab Core Toxin Proteins and Isolation of Spodoptera frugiperda Brush Border Membrane Vesicles for Use in Competitive Binding Experiments

The following examples evaluate the competition binding of Cry1 core toxin proteins to putative receptors in insect gut tissues. It is shown that 125I-labeled Cry1Ca core toxin protein binds with high affinity to Brush Border Membrane Vesicles (BBMV's) prepared from Spodoptera frugiperda (fall armyworm) and that Cry1Ab core toxin protein does not compete with this binding. In the alternative, it is shown that 125I-labeled Cry1Ab core toxin protein binds with high affinity to BBMV's prepared from S. frugiperda and that Cry1Ca core toxin protein does not compete with this binding.

Purification of Cry Proteins.

A gene encoding a chimeric DIG-152 protein, comprising the Cry1Ca3 core toxin and Cry1Ab protoxin, was expressed in the Pseudomonas fluorescens expression strain as described in Example 2. In similar fashion, a gene encoding a Cry1Ab protein was expressed in the Pf system. The P. fluorescens strain that expresses Cry1Ab protein was named DPf88.

The proteins were purified by the methods of Example 2, and trypsin digestion to produce activated core toxins from the full-length proteins was then performed, and the products were purified by the methods described in Example 2. Preparations of the trypsin processed (activated core toxin) proteins were >95% pure and had a molecular weight of approximately 65 kDa as determined experimentally by SDS-PAGE. As used herein, the activated core toxin prepared from the DIG-152 protein is called the Cry1Ca core toxin protein, and the activated core toxin prepared from the Cry1Ab protein is called the Cry1Ab core toxin protein.

Preparation and Fractionation of Solubilized BBMV's.

Standard methods of protein quantification and SDS-polyacrylamide gel electrophoresis were employed as taught, for example, in Sambrook et al. (1989) and Ausubel et al. (1995), and updates thereof.

Last instar S. frugiperda larvae were fasted overnight and then dissected after chilling on ice for 15 minutes. The midgut tissue was removed from the body cavity, leaving behind the hindgut attached to the integument. The midgut was placed in a 9× volume of ice cold homogenization buffer (300 mM mannitol, 5 mM EGTA, 17 mM Tris base, pH7.5), supplemented with Protease Inhibitor Cocktail (Sigma-Aldrich P-2714) diluted as recommended by the supplier. The tissue was homogenized with 15 strokes of a glass tissue homogenizer. BBMV's were prepared by the MgCl 2 precipitation method of Wolfersberger (1993). Briefly, an equal volume of a 24 mM MgCl 2 solution in 300 mM mannitol was mixed with the midgut homogenate, stirred for 5 minutes and allowed to stand on ice for 15 min. The solution was centrifuged at 2,500×g for 15 min at 4°. The supernatant was saved and the pellet suspended into the original volume of 0.5× diluted homogenization buffer and centrifuged again. The two supernatants were combined and centrifuged at 27,000×g for 30 min at 4° to form the BBMV fraction. The pellet was suspended into BBMV Storage Buffer (10 mM HEPES, 130 mM KCl, 10% glycerol, pH7.4) to a protein concentration of about 3 mg/mL. Protein concentration was determined using Bovine Serum Albumin (BSA) as the standard. Alkaline phosphatase determination (a marker enzyme for the BBMV fraction) was made prior to freezing the samples using the QuantiChrom™ DALP-250 Alkaline Phosphatase Assay Kit (Gentaur Molecular Products, Kampenhout, BE) following the manufacturer's instructions. The specific activity of this enzyme typically increased 7-fold compared to that found in the starting midgut homogenate fraction. The BBMV's were aliquoted into 250 μL samples, flash frozen in liquid nitrogen and stored at −80°.

Electrophoresis.

Analysis of proteins by SDS-PAGE was conducted under reducing (i.e. in 5% β-mercaptoethanol, BME) and denaturing (i.e. heated 5 minutes at 90° in the presence of 2% SDS) conditions. Proteins were loaded into wells of a 4% to 20% Tris-Glycine polyacrylamide gel (BioRad; Hercules, Calif.) and separated at 200 volts for 60 minutes. Protein bands were detected by staining with Coomassie Brilliant Blue R-250 (BioRad) for one hour, and destained with a solution of 5% methanol in 7% acetic acid. The gels were imaged and analyzed using a BioRad Fluoro-S Multi Imager™. Relative molecular weights of the protein bands were determined by comparison to the mobilities of known molecular weight proteins observed in a sample of BenchMark™ Protein Ladder (Life Technologies, Rockville, Md.) loaded into one well of the gel.

Iodination of Cry1Ca or Cry1Ab Core Toxin Proteins.

Purified Cry1Ca core toxin protein or Cry1Ab core toxin protein were iodinated using Pierce Iodination Beads (Thermo Fisher Scientific, Rockford, Ill.). Briefly, two Iodination Beads were washed twice with 500 μL of PBS (20 mM sodium phosphate, 0.15 M NaCl, pH7.5), and placed into a 1.5 mL centrifuge tube with 100 μL of PBS. 0.5 mCi of 125I-labeled sodium iodide was added, the components were allowed to react for 5 minutes at room temperature, then 1 μg of Cry1Ca core toxin protein (or 1 μg of Cry1Ab core toxin protein) was added to the solution and allowed to react for an additional 3 to 5 minutes. The reaction was terminated by pipetting the solution from the Iodination Beads and applying it to a Zeba™ spin column (Invitrogen) equilibrated in 50 mM CAPS, pH10.0, 1 mM DTT (dithiothreitol), 1 mM EDTA, and 5% glycerol. The Iodination Beads were washed twice with 10 μL of PBS and the wash solution was also applied to the Zeba™ desalting column. The radioactive solution was eluted through the spin column by centrifuging at 1,000×g for 2 min. 125I-radiolabeled Cry1Ca core toxin protein (or Cry1Ab core toxin protein) was then dialyzed against 50 mM CAPS, pH10.0, 1 mM DTT, 1 mM EDTA, and 5% glycerol.

Imaging.

Radio-purity of the iodinated Cry1Ca or Cry1Ab core toxin proteins was determined by SDS-PAGE and phosphorimaging. Briefly, SDS-PAGE gels were dried using a BioRad gel drying apparatus following the manufacturer's instructions. The dried gels were imaged by wrapping them in Mylar film (12 μm thick) and exposing them under a Molecular Dynamics storage phosphor screen (35 cm×43 cm) for 1 hour. The plates were developed using a Molecular Dynamics Storm 820 phosphorimager and the image was analyzed using ImageQuant™ software.

›Example 4

Binding of 125I-Labeled Cry1 Core Toxin Protein to BBMV's from Spodoptera frugiperda

A saturation curve was generated to determine the optimal amount of BBMV protein to use in the binding assays with Cry1Ca and Cry1Ab core toxin proteins. 0.5 nM of 125I-radiolabeled Cry1 core toxin protein was incubated for 1 hr at 28° in binding buffer (8 mM NaHPO 4 , 2 mM KH 2 PO 4 , 150 mM NaCl, 0.1% BSA, pH7.4) with amounts of BBMV protein ranging from 0 μg/mL to 500 μg/mL (total volume of 0.5 mL). 125I-labeled Cry1 core toxin protein bound to the BBMV proteins was separated from the unbound fraction by sampling 150 μL of the reaction mixture in triplicate into separate 1.5 mL centrifuge tubes and centrifuging the samples at 14,000×g for 8 minutes at room temperature. The supernatant was gently removed and the pellet was washed three times with ice cold binding buffer. The bottom of the centrifuge tube containing the pellet was cut off, placed into a 13×75 mm glass culture tube and the samples were counted for 5 minutes each in the gamma counter. CPM (counts per minute) obtained minus background CPM (reaction with no BBMV protein) was plotted versus BBMV protein concentration. In accordance with results reported by others (Luo et al. 1999), the optimal concentration of BBMV protein to use in the binding assays was determined to be 150 μg/mL.

›Example 5

Competitive Binding Assays to BBMVs from S. frugiperda with Core Toxin Proteins of Cry1Ab and Cry1Ca

Homologous and heterologous competition binding assays were conducted using 150 μg/mL of S. frugiperda BBMV protein and 0.5 nM of the 125I-radiolabeled Cry1Ca core toxin protein. Concentrations of the competitive non-radiolabeled Cry1Ab core toxin protein added to the reaction mixture ranged from 0.045 nM to 300 nM and were added at the same time as the radioactive Cry1Ca core toxin protein, to assure true binding competition. Incubations were carried out for 1 hr at 28° and the amount of 125I-labeled Cry1Ca core toxin protein bound to the BBMV (specific binding) was measured as described above. Non-specific binding was represented by the counts obtained in the presence of 1,000 nM of non-radiolabeled Cry1Ca core toxin protein. One hundred percent total binding was considered to be the amount of binding in the absence of any competitor Cry1Ab core toxin protein.

Receptor binding assays using 125I-labeled Cry1Ca core toxin protein determined the ability of the Cry1Ab core toxin protein to displace this radiolabeled ligand from its binding site on BBMV's from S. frugiperda . The results ( FIG. 1 ) show that the Cry1Ab core toxin protein did not displace bound 125I-labeled Cry1Ca core toxin protein from its receptor protein(s) at concentrations as high as 300 nM (600 times the concentration of the radioactive binding ligand). As expected, unlabeled Cry1Ca core toxin protein was able to displace radiolabeled Cry1Ca core toxin protein from its binding protein(s), exhibiting a sigmoidal dose response curve with 50% displacement occurring at 5 nM.

It is thus indicated that the Cry1Ca core toxin protein interacts with a binding site in S. frugiperda BBMVs that does not bind the Cry1Ab core toxin protein.

›Example 6

Competitive Binding Assays to BBMVs from S. frugiperda with Core Toxin Proteins of Cry1Ca and Cry1Ab

Homologous and heterologous competition binding assays were conducted using 150 μg/mL BBMV protein and 0.5 nM of the 125I-radiolabeled Cry1Ab core toxin protein. Concentrations of the competitive non-radiolabeled Cry1Ca core toxin protein added to the reaction mixture ranged from 0.045 nM to 1000 nM and were added at the same time as the radioactive Cry1Ab core toxin protein, to assure true binding competition. Incubations were carried out for 1 hr at 28° and the amount of 125I-labeled Cry1Ab core toxin protein bound to the BBMV (specific binding) was measured as described above. Non-specific binding was represented by the counts obtained in the presence of 1000 nM of non-radiolabeled Cry1Ab core toxin protein. One hundred percent total binding was considered to be the amount of binding in the absence of any competitor Cry1Ca core toxin protein.

Receptor binding assays using 125I-labeled Cry1Ab core toxin protein determined the ability of the Cry1Ca core toxin protein to displace this radiolabeled ligand from its binding site on BBMV's from S. frugiperda . The results ( FIG. 2 ) show that the Cry1Ca core toxin protein did not displace bound 125I-labeled Cry1Ab core toxin protein from its receptor protein(s) at concentrations as high as 300 nM (600 times the concentration of the radioactive binding ligand). As expected, unlabeled Cry1Ab core toxin protein was able to displace radiolabeled Cry1Ab core toxin protein from its binding protein(s), exhibiting a sigmoidal dose response curve with 50% displacement occurring at 5 nM.

It is thus indicated that the Cry1Ab core toxin protein interacts with a binding site in S. frugiperda BBMV that does not bind the Cry1Ca core toxin protein.

›REFERENCES

Finney, D. J. 1971. Probit analysis. Cambridge University Press, England.

Hua, G., L. Masson, J. L. Jurat-Fuentes, G. Schwab, and M. J. Adang. Binding analyses of Bacillus thuringiensis Cry d-endotoxins using brush border membrane vesicles of Ostrinia nubilalis . Applied and Environmental Microbiology 67[2], 872-879. 2001.

LeOra Software. 1987. POLO-PC. A user's guide to probit and logit analysis. Berkeley, Calif.

McGaughey, W. H., F. Gould, and W. Gelernter. Bt resistance management. Nature Biotechnology 16[2], 144-146. 1998

Marton, P. R. G. C., L. J. Young, K. Steffey, and B. D. Siegfried. 1999. Baseline susceptibility of the European corn borer, Ostrinia nubilalis (Hübner) (Lepidoptera: Pyralidae) to Bacillus thuringiensis toxins. J. Econ. Entomol. 92 (2): 280-285.

Robertson, L. J. and H. K. Preisler. 1992. Pesticide bioassays with arthropods. CRC Press, Boca Ranton, Fla.

SAS Institute Inc. 1988. SAS procedures guide, Release 6.03 edition. SAS Institute Inc, Cary, N.C.

Stone, B. F. 1968. A formula for determining degree of dominance in cases of monofactorial inheritance of resistance to chemicals. Bull. WHO 38:325-329.

Van Mellaert, H., J. Botterman, J. Van Rie, and H. Joos. Transgenic plants for the prevention of development of insects resistant to Bacillus thuringiensis toxins. (Plant Genetic Systems N.V., Belg. 89-401499[400246], 57-19901205. EP. May 31, 1989

›Tables in the description — 4
TABLE 1
Class of Amino AcidExamples of Amino Acids
NonpolarAla, Val, Leu, Ile, Pro, Met, Phe, Trp
Uncharged PolarGly, Ser, Thr, Cys, Tyr, Asn, Gly
AcidicAsp, Glu
BasicLys, Arg, His
TABLE 2 — Dose response larval mortality and growth inhibition (% mean ± sem) of Cry1Ab -susceptible (SCB) and Cry1Ab-resistant (rSCB) Diatraea saccharalis feeding on diet containing Cry1Ab or DIG-152 protein a
Cry1Ab proteinDIG-152
protein#protein#
Insectconc'n blarvaeMortality c% GI dconc'n blarvaeMortality c% GI e
SCBBlank1263.2 ± 1.3 a—Blank12410.4 ± 3.2 b5.9 ± 4.8 a
rSCBBlank1284.7 ± 2.0 a—Blank1254.1 ± 2.5 a3.1 ± 5.5 a
SCBBufferNT fBuffer12110.9 ± 3.9 b—
rSCBBufferNTBuffer1271.6 ± 0.9 a—
SCB0.0312512438.6 ± 4.8 c90.7 ± 1.6 ef0.0312653.1 ± 2.3 c69.5 ± 6.5 c
rSCB0.031251238.3 ± 3.2 ab−15.9 ± 4.6 a0.031273.2 ± 0.0 a8.0 ± 5.1 a
SCB0.12512834.3 ± 7.9 c87.4 ± 2.5 e0.112788.2 ± 3.5 d100 ± 0.0 d
rSCB0.1251268.6 ± 2.3 ab10.0 ± 5.3 b0.112711.8 ± 0.8 b49.0 ± 3.5 b
SCB0.511975.6 ± 2.9 e94.3 ± 1.0 fg0.413096.2 ± 1.9 e100 ± 0.0 d
rSCB0.51285.5 ± 1.5 a26.7 ± 3.1 c0.412591.2 ± 2.0 d100 ± 0.0 d
SCB212593.6 ± 2.2 f100 ± 0.0 g1.6122100 ± 0.0 f100 ± 0.0 d
rSCB212814.8 ± 2.7 b67.5 ± 1.5 d1.6127100 ± 0.0 f100 ± 0.0 d
SCB812295.9 ± 1.6 fg100 ± 0.0 g6.4125100 ± 0.0 f100 ± 0.0 d
rSCB812040.6 ± 5.1 c85.2 ± 1.9 e6.4128100 ± 0.0 f100 ± 0.0 d
SCB3212699.2 ± 0.8 g100 ± 0.0 g25.678100 ± 0.0 f100 ± 0.0 d
rSCB3212860.9 ± 5.8 d90.3 ± 2.2 ef25.6119100 ± 0.0 f100 ± 0.0 d
SCB10260100 ± 0.0 f100 ± 0.0 d
rSCB102126100 ± 0.0 f100 ± 0.0 d
a Mean values within a column across all treatments followed by a same letter are not significantly different (P < 0.05; LSMEANS test). sem = standard error of the mean
b μg protein/gm diet
c The measure of larval mortality was as defined in the text.
d These percent values were calculated using the formula described in the text.
e These percent values were calculated using the formula described in the text.
f NT = Not Tested
TABLE 3 — Summary of bioassay tests on larvae of SCB and rSCB using insect diet into which DIG-152 protein or Cry1Ab protein was incorporated. a The measure of larval mortality was defined as described in the text. b Resistance ratios with a letter ‘S’ are Significant, while those with letters ‘NS” are Not Significant at the 5% level based on lethal dose tests.
Insect# larvae testedLC 50 (95% CI) (μg/gm) aRR b
DIG-152SCB5050.03(0.02-0.03)6.0 NS
rSCB5060.18(0.15-0.24)
Cry1AbSCB7440.13(0.08-0.20142 S
rSCB44018.46(13.93-26.29
APPENDIX A List of delta-endotoxins—from Crickmore et al. website (cited in application) Accession Number is to NCBI entry (if available)
NameAcc No.AuthorsYearSource StrainComment
Cry1Aa1AAA22353Schnepf et al1985Bt kurstaki HD1
Cry1Aa2AAA22552Shibano et al1985Bt sotto
Cry1Aa3BAA00257Shimizu et al1988Bt aizawai IPL7
Cry1Aa4CAA31886Masson et al1989Bt entomocidus
Cry1Aa5BAA04468Udayasuriyan et al1994Bt Fu-2-7
Cry1Aa6AAA86265Masson et al1994Bt kurstaki NRD-12
Cry1Aa7AAD46139Osman et al1999Bt C12
Cry1Aa8I26149Liu1996DNA sequence only
Cry1Aa9BAA77213Nagamatsu et al1999Bt dendrolimus T84A1
Cry1Aa10AAD55382Hou and Chen1999Bt kurstaki HD-1-02
Cry1Aa11CAA70856Tounsi et al1999Bt kurstaki
Cry1Aa12AAP80146Yao et al2001Bt Ly30
Cry1Aa13AAM44305Zhong et al2002Bt sotto
Cry1Aa14AAP40639Ren et al2002unpublished
Cry1Aa15AAY66993Sauka et al2005Bt INTA Mol-12
Cry1Ab1AAA22330Wabiko et al1986Bt berliner 1715
Cry1Ab2AAA22613Thorne et al1986Bt kurstaki
Cry1Ab3AAA22561Geiser et al1986Bt kurstaki HD1
Cry1Ab4BAA00071Kondo et al1987Bt kurstaki HD1
Cry1Ab5CAA28405Hofte et al1986Bt berliner 1715
Cry1Ab6AAA22420Hefford et al1987Bt kurstaki NRD-12
Cry1Ab7CAA31620Haider & Ellar1988Bt aizawai IC1
Cry1Ab8AAA22551Oeda et al1987Bt aizawai IPL7
Cry1Ab9CAA38701Chak & Jen1993Bt aizawai HD133
Cry1Ab10A29125Fischhoff et al1987Bt kurstaki HD1
Cry1Ab11I12419Ely & Tippett1995Bt A20DNA sequence only
Cry1Ab12AAC64003Silva-Werneck et al1998Bt kurstaki S93
Cry1Ab13AAN76494Tan et al2002Bt c005
Cry1Ab14AAG16877Meza-Basso & Theoduloz2000Native Chilean Bt
Cry1Ab15AAO13302Li et al2001Bt B-Hm-16
Cry1Ab16AAK55546Yu et al2002Bt AC-11
Cry1Ab17AAT46415Huang et al2004Bt WB9
Cry1Ab18AAQ88259Stobdan et al2004Bt
Cry1Ab19AAW31761Zhong et al2005Bt X-2
Cry1Ab20ABB72460Liu et al2006BtC008
Cry1Ab21ABS18384Swiecicka et al2007Bt IS5056
Cry1Ab22ABW87320Wu and Feng2008BtS2491Ab
Cry1Ab-likeAAK14336Nagarathinam et al2001Bt kunthala RX24uncertain sequence
Cry1Ab-likeAAK14337Nagarathinam et al2001Bt kunthala RX28uncertain sequence
Cry1Ab-likeAAK14338Nagarathinam et al2001Bt kunthala RX27uncertain sequence
Cry1Ab-likeABG88858Lin et al2006Bt ly4a3insufficient sequence
Cry1Ac1AAA22331Adang et al1985Bt kurstaki HD73
Cry1Ac2AAA22338Von Tersch et al1991Bt kenyae
Cry1Ac3CAA38098Dardenne et al1990Bt BTS89A
Cry1Ac4AAA73077Feitelson1991Bt kurstaki PS85A1
Cry1Ac5AAA22339Feitelson1992Bt kurstaki PS81GG
Cry1Ac6AAA86266Masson et al1994Bt kurstaki NRD-12
Cry1Ac7AAB46989Herrera et al1994Bt kurstaki HD73
Cry1Ac8AAC44841Omolo et al1997Bt kurstaki HD73
Cry1Ac9AAB49768Gleave et al1992Bt DSIR732
Cry1Ac10CAA05505Sun1997Bt kurstaki YBT-1520
Cry1Ac11CAA10270Makhdoom & Riazuddin1998
Cry1Ac12I12418Ely & Tippett1995Bt A20DNA sequence only
Cry1Ac13AAD38701Qiao et al1999Bt kurstaki HD1
Cry1Ac14AAQ06607Yao et al2002Bt Ly30
Cry1Ac15AAN07788Tzeng et al2001Bt from Taiwan
Cry1Ac16AAU87037Zhao et al2005Bt H3
Cry1Ac17AAX18704Hire et al2005Bt kenyae HD549
Cry1Ac18AAY88347Kaur & Allam2005Bt SK-729
Cry1Ac19ABD37053Gao et al2005Bt C-33
Cry1Ac20ABB89046Tan et al2005
Cry1Ac21AAY66992Sauka et al2005INTA Mol-12
Cry1Ac22ABZ01836Zhang & Fang2008Bt W015-1
Cry1Ac23CAQ30431Kashyap et al2008Bt
Cry1Ac24ABL01535Arango et al2008Bt 146-158-01
Cry1Ac25FJ513324Guan Peng et al2008Bt Tm37-6No NCBI link July 2009
Cry1Ac26FJ617446Guan Peng et al2009Bt Tm41-4No NCBI link July 2009
Cry1Ac27FJ617447Guan Peng et al2009Bt Tm44-1BNo NCBI link July 2009
Cry1Ac28ACM90319Li et al2009Bt Q-12
Cry1Ad1AAA22340Feitelson1993Bt aizawai PS81I
Cry1Ad2CAA01880Anonymous1995Bt PS81RR1
Cry1Ae1AAA22410Lee & Aronson1991Bt alesti
Cry1Af1AAB82749Kang et al1997Bt NT0423
Cry1Ag1AAD46137Mustafa1999
Cry1Ah1AAQ14326Tan et al2000
Cry1Ah2ABB76664Qi et al2005Bt alesti
Cry1Ai1AAO39719Wang et al2002
Cry1A-likeAAK14339Nagarathinam et al2001Bt kunthala nags3uncertain sequence
Cry1Ba1CAA29898Brizzard & Whiteley1988Bt thuringiensis HD2
Cry1Ba2CAA65003Soetaert1996Bt entomocidus HD110
Cry1Ba3AAK63251Zhang et al2001
Cry1Ba4AAK51084Nathan et al2001Bt entomocidus HD9
Cry1Ba5ABO20894Song et al2007Bt sfw-12
Cry1Ba6ABL60921Martins et al2006Bt S601
Cry1Bb1AAA22344Donovan et al1994Bt EG5847
Cry1Bc1CAA86568Bishop et al1994Bt morrisoni
Cry1Bd1AAD10292Kuo et al2000Bt wuhanensis HD525
Cry1Bd2AAM93496Isakova et al2002Bt 834
Cry1Be1AAC32850Payne et al1998Bt PS158C2
Cry1Be2AAQ52387Baum et al2003
Cry1Be3FJ716102Xiaodong Sun et al2009BtNo NCBI link July 2009
Cry1Bf1CAC50778Arnaut et al2001
Cry1Bf2AAQ52380Baum et al2003
Cry1Bg1AAO39720Wang et al2002
Cry1Ca1CAA30396Honee et al1988Bt entomocidus 60.5
Cry1Ca2CAA31951Sanchis et al1989Bt aizawai 7.29
Cry1Ca3AAA22343Feitelson1993Bt aizawai PS81I
Cry1Ca4CAA01886Van Mellaert et al1990Bt entomocidus HD110
Cry1Ca5CAA65457Strizhov1996Bt aizawai 7.29
Cry1Ca6AAF37224Yu et al2000Bt AF-2
Cry1Ca7AAG50438Aixing et al2000Bt J8
Cry1Ca8AAM00264Chen et al2001Bt c002
Cry1Ca9AAL79362Kao et al2003Bt G10-01A
Cry1Ca10AAN16462Lin et al2003Bt E05-20a
Cry1Ca11AAX53094Cai et al2005Bt C-33
Cry1Cb1M97880Kalman et al1993Bt galleriae HD29DNA sequence only
Cry1Cb2AAG35409Song et al2000Bt c001
Cry1Cb3ACD50894Huang et al2008Bt 087
Cry1Cb-likeAAX63901Thammasittirong et al2005Bt TA476-1insufficient sequence
Cry1Da1CAA38099Hofte et al1990Bt aizawai HD68
Cry1Da2I76415Payne & Sick1997DNA sequence only
Cry1Db1CAA80234Lambert1993Bt BTS00349A
Cry1Db2AAK48937Li et al2001Bt B-Pr-88
Cry1Dc1ABK35074Lertwiriyawong et al2006Bt JC291
Cry1Ea1CAA37933Visser et al1990Bt kenyae 4F1
Cry1Ea2CAA39609Bosse et al1990Bt kenyae
Cry1Ea3AAA22345Feitelson1991Bt kenyae PS81F
Cry1Ea4AAD04732Barboza-Corona et al1998Bt kenyae LBIT-147
Cry1Ea5A15535Botterman et al1994DNA sequence only
Cry1Ea6AAL50330Sun et al1999Bt YBT-032
Cry1Ea7AAW72936Huehne et al2005Bt JC190
Cry1Ea8ABX11258Huang et al2007Bt HZM2
Cry1Eb1AAA22346Feitelson1993Bt aizawai PS81A2
Cry1Fa1AAA22348Chambers et al1991Bt aizawai EG6346
Cry1Fa2AAA22347Feitelson1993Bt aizawai PS81I
Cry1Fb1CAA80235Lambert1993Bt BTS00349A
Cry1Fb2BAA25298Masuda & Asano1998Bt morrisoni INA67
Cry1Fb3AAF21767Song et al1998Bt morrisoni
Cry1Fb4AAC10641Payne et al1997
Cry1Fb5AAO13295Li et al2001Bt B-Pr-88
Cry1Fb6ACD50892Huang et al2008Bt 012
Cry1Fb7ACD50893Huang et al2008Bt 087
Cry1Ga1CAA80233Lambert1993Bt BTS0349A
Cry1Ga2CAA70506Shevelev et al1997Bt wuhanensis
Cry1Gb1AAD10291Kuo & Chak1999Bt wuhanensis HD525
Cry1Gb2AAO13756Li et al2000Bt B-Pr-88
Cry1GcAAQ52381Baum et al2003
Cry1Ha1CAA80236Lambert1993Bt BTS02069AA
Cry1Hb1AAA79694Koo et al1995Bt morrisoni BF190
Cry1H-likeAAF01213Srifah et al1999Bt JC291insufficient sequence
Cry1Ia1CAA44633Tailor et al1992Bt kurstaki
Cry1Ia2AAA22354Gleave et al1993Bt kurstaki
Cry1Ia3AAC36999Shin et al1995Bt kurstaki HD1
Cry1Ia4AAB00958Kostichka et al1996Bt AB88
Cry1Ia5CAA70124Selvapandiyan1996Bt 61
Cry1Ia6AAC26910Zhong et al1998Bt kurstaki S101
Cry1Ia7AAM73516Porcar et al2000Bt
Cry1Ia8AAK66742Song et al2001
Cry1Ia9AAQ08616Yao et al2002Bt Ly30
Cry1Ia10AAP86782Espindola et al2003Bt thuringiensis
Cry1Ia11CAC85964Tounsi et al2003Bt kurstaki BNS3
Cry1Ia12AAV53390Grossi de Sa et al2005Bt
Cry1Ia13ABF83202Martins et al2006Bt
Cry1Ia14ACG63871Liu & Guo2008Bt11
Cry1Ia15FJ617445Guan Peng et al2009Bt E-1BNo NCBI link July 2009
Cry1Ia16FJ617448Guan Peng et al2009Bt E-1ANo NCBI link July 2009
Cry1Ib1AAA82114Shin et al1995Bt entomocidus BP465
Cry1Ib2ABW88019Guan et al2007Bt PP61
Cry1Ib3ACD75515Liu & Guo2008Bt GS8
Cry1Ic1AAC62933Osman et al1998Bt C18
Cry1Ic2AAE71691Osman et al2001
Cry1Id1AAD44366Choi2000
Cry1Ie1AAG43526Song et al2000Bt BTC007
Cry1If1AAQ52382Baum et al2003
Cry1I-likeAAC31094Payne et al1998insufficient sequence
Cry1I-likeABG88859Lin & Fang2006Bt ly4a3insufficient sequence
Cry1Ja1AAA22341Donovan1994Bt EG5847
Cry1Jb1AAA98959Von Tersch & Gonzalez1994Bt EG5092
Cry1Jc1AAC31092Payne et al1998
Cry1Jc2AAQ52372Baum et al2003
Cry1Jd1CAC50779Arnaut et al2001Bt
Cry1Ka1AAB00376Koo et al1995Bt morrisoni BF190
Cry1La1AAS60191Je et al2004Bt kurstaki K1
Cry1-likeAAC31091Payne et al1998insufficient sequence
Cry2Aa1AAA22335Donovan et al1989Bt kurstaki
Cry2Aa2AAA83516Widner & Whiteley1989Bt kurstaki HD1
Cry2Aa3D86064Sasaki et al1997Bt sottoDNA sequence only
Cry2Aa4AAC04867Misra et al1998Bt kenyae HD549
Cry2Aa5CAA10671Yu & Pang1999Bt SL39
Cry2Aa6CAA10672Yu & Pang1999Bt YZ71
Cry2Aa7CAA10670Yu & Pang1999Bt CY29
Cry2Aa8AAO13734Wei et al2000Bt Dongbei 66
Cry2Aa9AAO13750Zhang et al2000
Cry2Aa10AAQ04263Yao et al2001
Cry2Aa11AAQ52384Baum et al2003
Cry2Aa12ABI83671Tan et al2006Bt Rpp39
Cry2Aa13ABL01536Arango et al2008Bt 146-158-01
Cry2Aa14ACF04939Hire et al2008Bt HD-550
Cry2Ab1AAA22342Widner & Whiteley1989Bt kurstaki HD1
Cry2Ab2CAA39075Dankocsik et al1990Bt kurstaki HD1
Cry2Ab3AAG36762Chen et al1999Bt BTC002
Cry2Ab4AAO13296Li et al2001Bt B-Pr-88
Cry2Ab5AAQ04609Yao et al2001Bt ly30
Cry2Ab6AAP59457Wang et al2003Bt WZ-7
Cry2Ab7AAZ66347Udayasuriyan et al2005Bt 14-1
Cry2Ab8ABC95996Huang et al2006Bt WB2
Cry2Ab9ABC74968Zhang et al2005Bt LLB6
Cry2Ab10EF157306Lin et al2006Bt LyD
Cry2Ab11CAM84575Saleem et al2007Bt CMBL-BT1
Cry2Ab12ABM21764Lin et al2007Bt LyD
Cry2Ab13ACG76120Zhu et al2008Bt ywc5-4
Cry2Ab14ACG76121Zhu et al2008Bt Bts
Cry2Ac1CAA40536Aronson1991Bt shanghai S1
Cry2Ac2AAG35410Song et al2000
Cry2Ac3AAQ52385Baum et al2003
Cry2Ac4ABC95997Huang et al2006Bt WB9
Cry2Ac5ABC74969Zhang et al2005
Cry2Ac6ABC74793Xia et al2006Bt wuhanensis
Cry2Ac7CAL18690Saleem et al2008Bt SBSBT-1
Cry2Ac8CAM09325Saleem et al2007Bt CMBL-BT1
Cry2Ac9CAM09326Saleem et al2007Bt CMBL-BT2
Cry2Ac10ABN15104Bai et al2007Bt QCL-1
Cry2Ac11CAM83895Saleem et al2007Bt HD29
Cry2Ac12CAM83896Saleem et al2007Bt CMBL-BT3
Cry2Ad1AAF09583Choi et al1999Bt BR30
Cry2Ad2ABC86927Huang et al2006Bt WB10
Cry2Ad3CAK29504Saleem et al2006Bt 5_2AcT(1)
Cry2Ad4CAM32331Saleem et al2007Bt CMBL-BT2
Cry2Ad5CAO78739Saleem et al2007Bt HD29
Cry2Ae1AAQ52362Baum et al2003
Cry2Af1ABO30519Beard et al2007Bt C81
Cry2AgACH91610Zhu et al2008Bt JF19-2
Cry2AhEU939453Zhang et al2008BtNo NCBI link July 2009
Cry2Ah2ACL80665Zhang et al2009Bt BRC-ZQL3
Cry2AiFJ788388Udayasuriyan et al2009BtNo NCBI link July 2009
Cry3Aa1AAA22336Herrnstadt et al1987Bt san diego
Cry3Aa2AAA22541Sekar et al1987Bt tenebrionis
Cry3Aa3CAA68482Hofte et al1987
Cry3Aa4AAA22542McPherson et al1988Bt tenebrionis
Cry3Aa5AAA50255Donovan et al1988Bt morrisoni EG2158
Cry3Aa6AAC43266Adams et al1994Bt tenebrionis
Cry3Aa7CAB41411Zhang et al1999Bt 22
Cry3Aa8AAS79487Gao and Cai2004Bt YM-03
Cry3Aa9AAW05659Bulla and Candas2004Bt UTD-001
Cry3Aa10AAU29411Chen et al2004Bt 886
Cry3Aa11AAW82872Kurt et al2005Bt tenebrionis Mm2
Cry3Aa12ABY49136Sezen et al2008Bt tenebrionis
Cry3Ba1CAA34983Sick et al1990Bt tolworthi 43F
Cry3Ba2CAA00645Peferoen et al1990Bt PGSI208
Cry3Bb1AAA22334Donovan et al1992Bt EG4961
Cry3Bb2AAA74198Donovan et al1995Bt EG5144
Cry3Bb3I15475Peferoen et al1995DNA sequence only
Cry3Ca1CAA42469Lambert et al1992Bt kurstaki BtI109P
Cry4Aa1CAA68485Ward & Ellar1987Bt israelensis
Cry4Aa2BAA00179Sen et al1988Bt israelensis HD522
Cry4Aa3CAD30148Berry et al2002Bt israelensis
Cry4A-likeAAY96321Mahalakshmi et al2005Bt LDC-9insufficient sequence
Cry4Ba1CAA30312Chungjatpornchai et al1988Bt israelensis 4Q2-72
Cry4Ba2CAA30114Tungpradubkul et al1988Bt israelensis
Cry4Ba3AAA22337Yamamoto et al1988Bt israelensis
Cry4Ba4BAA00178Sen et al1988Bt israelensis HD522
Cry4Ba5CAD30095Berry et al2002Bt israelensis
Cry4Ba-likeABC47686Mahalakshmi et al2005Bt LDC-9insufficient sequence
Cry4Ca1EU646202Shu et al2008No NCBI link July 2009
Cry4Cb1FJ403208Jun & Furong2008Bt HS18-1No NCBI link July 2009
Cry4Cb2FJ597622Jun & Furong2008BT Ywc2-8No NCBI link July 2009
Cry4Cc1FJ403207Jun & Furong2008Bt MC28No NCBI link July 2009
Cry5Aa1AAA67694Narva et al1994Bt darmstadiensis PS17
Cry5Ab1AAA67693Narva et al1991Bt darmstadiensis PS17
Cry5Ac1I34543Payne et al1997DNA sequence only
Cry5Ad1ABQ82087Lenane et al2007Bt L366
Cry5Ba1AAA68598Foncerrada & Narva1997Bt PS86Q3
Cry5Ba2ABW88932Guo et al2008YBT 1518
Cry6Aa1AAA22357Narva et al1993Bt PS52A1
Cry6Aa2AAM46849Bai et al2001YBT 1518
Cry6Aa3ABH03377Jia et al2006Bt 96418
Cry6Ba1AAA22358Narva et al1991Bt PS69D1
Cry7Aa1AAA22351Lambert et al1992Bt galleriae PGSI245
Cry7Ab1AAA21120Narva & Fu1994Bt dakota HD511
Cry7Ab2AAA21121Narva & Fu1994Bt kumamotoensis 867
Cry7Ab3ABX24522Song et al2008Bt WZ-9
Cry7Ab4EU380678Shu et al2008BtNo NCBI link July 2009
Cry7Ab5ABX79555Aguirre-Arzola et al2008Bt monterrey GM-33
Cry7Ab6ACI44005Deng et al2008Bt HQ122
Cry7Ab7FJ940776Wang et al2009No NCBI link September 2009
Cry7Ab8GU145299Feng Jing2009No NCBI link November 2009
Cry7Ba1ABB70817Zhang et al2006Bt huazhongensis
Cry7Ca1ABR67863Gao et al2007Bt BTH-13
Cry7Da1ACQ99547Yi et al2009Bt LH-2
Cry8Aa1AAA21117Narva & Fu1992Bt kumamotoensis
Cry8Ab1EU044830Cheng et al2007Bt B-JJXNo NCBI link July 2009
Cry8Ba1AAA21118Narva & Fu1993Bt kumamotoensis
Cry8Bb1CAD57542Abad et al2002
Cry8Bc1CAD57543Abad et al2002
Cry8Ca1AAA21119Sato et al.1995Bt japonensis Buibui
Cry8Ca2AAR98783Shu et al2004Bt HBF-1
Cry8Ca3EU625349Du et al2008Bt FTL-23No NCBI link July 2009
Cry8Da1BAC07226Asano et al2002Bt galleriae
Cry8Da2BD133574Asano et al2002BtDNA sequence only
Cry8Da3BD133575Asano et al2002BtDNA sequence only
Cry8Db1BAF93483Yamaguchi et al2007Bt BBT2-5
Cry8Ea1AAQ73470Fuping et al2003Bt 185
Cry8Ea2EU047597Liu et al2007Bt B-DLLNo NCBI link July 2009
Cry8Fa1AAT48690Shu et al2004Bt 185also AAW81032
Cry8Ga1AAT46073Shu et al2004Bt HBF-18
Cry8Ga2ABC42043Yan et al2008Bt 145
Cry8Ga3FJ198072Xiaodong et al2008Bt FCD114No NCBI link July 2009
Cry8Ha1EF465532Fuping et al2006Bt 185No NCBI link July 2009
Cry8Ia1EU381044Yan et al2008Bt su4No NCBI link July 2009
Cry8Ja1EU625348Du et al2008Bt FPT-2No NCBI link July 2009
Cry8Ka1FJ422558Quezado et al2008No NCBI link July 2009
Cry8Ka2ACN87262Noguera & Ibarra2009Bt kenyae
Cry8-likeFJ770571Noguera & Ibarra2009Bt canadensisDNA sequence only
Cry8-likeABS53003Mangena et al2007Bt
Cry9Aa1CAA41122Shevelev et al1991Bt galleriae
Cry9Aa2CAA41425Gleave et al1992Bt DSIR517
Cry9Aa3GQ249293Su et al2009Bt SC5(D2)No NCBI link July 2009
Cry9Aa4GQ249294Su et al2009Bt T03C001No NCBI link July 2009
Cry9Aa likeAAQ52376Baum et al2003incomplete sequence
Cry9Ba1CAA52927Shevelev et al1993Bt galleriae
Cry9Bb1AAV28716Silva-Werneck et al2004Bt japonensis
Cry9Ca1CAA85764Lambert et al1996Bt tolworthi
Cry9Ca2AAQ52375Baum et al2003
Cry9Da1BAA19948Asano1997Bt japonensis N141
Cry9Da2AAB97923Wasano & Ohba1998Bt japonensis
Cry9Da3GQ249295Su et al2009Bt T03B001No NCBI link July 2009
Cry9Da4GQ249297Su et al2009Bt T03B001No NCBI link July 2009
Cry9Db1AAX78439Flannagan & Abad2005Bt kurstaki DP1019
Cry9Ea1BAA34908Midoh & Oyama1998Bt aizawai SSK-10
Cry9Ea2AAO12908Li et al2001Bt B-Hm-16
Cry9Ea3ABM21765Lin et al2006Bt lyA
Cry9Ea4ACE88267Zhu et al2008Bt ywc5-4
Cry9Ea5ACF04743Zhu et al2008Bts
Cry9Ea6ACG63872Liu & Guo2008Bt 11
Cry9Ea7FJ380927Sun et al2008No NCBI link July 2009
Cry9Ea8GQ249292Su et al2009GQ249292No NCBI link July 2009
Cry9Eb1CAC50780Arnaut et al2001
Cry9Eb2GQ249298Su et al2009Bt T03B001No NCBI link July 2009
Cry9Ec1AAC63366Wasano et al2003Bt galleriae
Cry9Ed1AAX78440Flannagan & Abad2005Bt kurstaki DP1019
Cry9Ee1GQ249296Su et al2009Bt T03B001No NCBI link August 2009
Cry9-likeAAC63366Wasano et al1998Bt galleriaeinsufficient sequence
Cry10Aa1AAA22614Thorne et al1986Bt israelensis
Cry10Aa2E00614Aran & Toomasu1996Bt israelensis ONR-60ADNA sequence only
Cry10Aa3CAD30098Berry et al2002Bt israelensis
Cry10A-likeDQ167578Mahalakshmi et al2006Bt LDC-9incomplete sequence
Cry11Aa1AAA22352Donovan et al1988Bt israelensis
Cry11Aa2AAA22611Adams et al1989Bt israelensis
Cry11Aa3CAD30081Berry et al2002Bt israelensis
Cry11Aa-likeDQ166531Mahalakshmi et al2007Bt LDC-9incomplete sequence
Cry11Ba1CAA60504Delecluse et al1995Bt jegathesan 367
Cry11Bb1AAC97162Orduz et al1998Bt medellin
Cry12Aa1AAA22355Narva et al1991Bt PS33F2
Cry13Aa1AAA22356Narva et al1992Bt PS63B
Cry14Aa1AAA21516Narva et al1994Bt sotto PS80JJ1
Cry15Aa1AAA22333Brown & Whiteley1992Bt thompsoni
Cry16Aa1CAA63860Barloy et al1996Cb malaysia CH18
Cry17Aa1CAA67841Barloy et al1998Cb malaysia CH18
Cry18Aa1CAA67506Zhang et al1997Paenibacillus popilliae
Cry18Ba1AAF89667Patel et al1999Paenibacillus popilliae
Cry18Ca1AAF89668Patel et al1999Paenibacillus popilliae
Cry19Aa1CAA68875Rosso & Delecluse1996Bt jegathesan 367
Cry19Ba1BAA32397Hwang et al1998Bt higo
Cry20Aa1AAB93476Lee & Gill1997Bt fukuokaensis
Cry20Ba1ACS93601Noguera & Ibarra2009Bt higo LBIT-976
Cry20-likeGQ144333Yi et al2009Bt Y-5DNA sequence only
Cry21Aa1I32932Payne et al1996DNA sequence only
Cry21Aa2I66477Feitelson1997DNA sequence only
Cry21Ba1BAC06484Sato & Asano2002Bt roskildiensis
Cry22Aa1I34547Payne et al1997DNA sequence only
Cry22Aa2CAD43579Isaac et al2002Bt
Cry22Aa3ACD93211Du et al2008Bt FZ-4
Cry22Ab1AAK50456Baum et al2000Bt EG4140
Cry22Ab2CAD43577Isaac et al2002Bt
Cry22Ba1CAD43578Isaac et al2002Bt
Cry23Aa1AAF76375Donovan et al2000BtBinary with Cry37Aa1
Cry24Aa1AAC61891Kawalek and Gill1998Bt jegathesan
Cry24Ba1BAD32657Ohgushi et al2004Bt sotto
Cry24Ca1CAJ43600Beron & Salerno2005Bt FCC-41
Cry25Aa1AAC61892Kawalek and Gill1998Bt jegathesan
Cry26Aa1AAD25075Wojciechowska et al1999Bt finitimus B-1166
Cry27Aa1BAA82796Saitoh1999Bt higo
Cry28Aa1AAD24189Wojciechowska et al1999Bt finitimus B-1161
Cry28Aa2AAG00235Moore and Debro2000Bt finitimus
Cry29Aa1CAC80985Delecluse et al2000Bt medellin
Cry30Aa1CAC80986Delecluse et al2000Bt medellin
Cry30Ba1BAD00052Ito et al2003Bt entomocidus
Cry30Ca1BAD67157Ohgushi et al2004Bt sotto
Cry30Ca2ACU24781Sun and Park2009Bt jegathesan 367
Cry30Da1EF095955Shu et al2006Bt Y41No NCBI link July 2009
Cry30Db1BAE80088Kishida et al2006Bt aizawai BUN1-14
Cry30Ea1ACC95445Fang et al2007Bt S2160-1
Cry30Ea2FJ499389Jun et al2008Bt Ywc2-8No NCBI link July 2009
Cry30Fa1ACI22625Tan et al2008Bt MC28
Cry30Ga1ACG60020Zhu et al2008Bt HS18-1
Cry31Aa1BAB11757Saitoh & Mizuki2000Bt 84-HS-1-11
Cry31Aa2AAL87458Jung and Cote2000Bt M15
Cry31Aa3BAE79808Uemori et al2006Bt B0195
Cry31Aa4BAF32571Yasutake et al2006Bt 79-25
Cry31Aa5BAF32572Yasutake et al2006Bt 92-10
Cry31Ab1BAE79809Uemori et al2006Bt B0195
Cry31Ab2BAF32570Yasutake et al2006Bt 31-5
Cry31Ac1BAF34368Yasutake et al2006Bt 87-29
Cry32Aa1AAG36711Balasubramanian et al2001Bt yunnanensis
Cry32Ba1BAB78601Takebe et al2001Bt
Cry32Ca1BAB78602Takebe et al2001Bt
Cry32Da1BAB78603Takebe et al2001Bt
Cry33Aa1AAL26871Kim et al2001Bt dakota
Cry34Aa1AAG50341Ellis et al2001Bt PS80JJ1Binary with Cry35Aa1
Cry34Aa2AAK64560Rupar et al2001Bt EG5899Binary with Cry35Aa2
Cry34Aa3AAT29032Schnepf et al2004Bt PS69QBinary with Cry35Aa3
Cry34Aa4AAT29030Schnepf et al2004Bt PS185GGBinary with Cry35Aa4
Cry34Ab1AAG41671Moellenbeck et al2001Bt PS149B1Binary with Cry35Ab1
Cry34Ac1AAG50118Ellis et al2001Bt PS167H2Binary with Cry35Ac1
Cry34Ac2AAK64562Rupar et al2001Bt EG9444Binary with Cry35Ab2
Cry34Ac3AAT29029Schnepf et al2004Bt KR1369Binary with Cry35Ab3
Cry34Ba1AAK64565Rupar et al2001Bt EG4851Binary with Cry35Ba1
Cry34Ba2AAT29033Schnepf et al2004Bt PS201L3Binary with Cry35Ba2
Cry34Ba3AAT29031Schnepf et al2004Bt PS201HH2Binary with Cry35Ba3
Cry35Aa1AAG50342Ellis et al2001Bt PS80JJ1Binary with Cry34Aa1
Cry35Aa2AAK64561Rupar et al2001Bt EG5899Binary with Cry34Aa2
Cry35Aa3AAT29028Schnepf et al2004Bt PS69QBinary with Cry34Aa3
Cry35Aa4AAT29025Schnepf et al2004Bt PS185GGBinary with Cry34Aa4
Cry35Ab1AAG41672Moellenbeck et al2001Bt PS149B1Binary with Cry34Ab1
Cry35Ab2AAK64563Rupar et al2001Bt EG9444Binary with Cry34Ac2
Cry35Ab3AY536891AAT290242004Bt KR1369Binary with Cry34Ab3
Cry35Ac1AAG50117Ellis et al2001Bt PS167H2Binary with Cry34Ac1
Cry35Ba1AAK64566Rupar et al2001Bt EG4851Binary with Cry34Ba1
Cry35Ba2AAT29027Schnepf et al2004Bt PS201L3Binary with Cry34Ba2
Cry35Ba3AAT29026Schnepf et al2004Bt PS201HH2Binary with Cry34Ba3
Cry36Aa1AAK64558Rupar et al2001Bt
Cry37Aa1AAF76376Donovan et al2000BtBinary with Cry23Aa
Cry38Aa1AAK64559Rupar et al2000Bt
Cry39Aa1BAB72016Ito et al2001Bt aizawai
Cry40Aa1BAB72018Ito et al2001Bt aizawai
Cry40Ba1BAC77648Ito et al2003Bun1-14
Cry40Ca1EU381045Shu et al2008Bt Y41No NCBI link July 2009
Cry40Da1ACF15199Zhang et al2008Bt S2096-2
Cry41Aa1BAD35157Yamashita et al2003Bt A1462
Cry41Ab1BAD35163Yamashita et al2003Bt A1462
Cry42Aa1BAD35166Yamashita et al2003Bt A1462
Cry43Aa1BAD15301Yokoyama and Tanaka2003P. lentimorbus semadara
Cry43Aa2BAD95474Nozawa2004P. popilliae popilliae
Cry43Ba1BAD15303Yokoyama and Tanaka2003P. lentimorbus semadara
Cry43-likeBAD15305Yokoyama and Tanaka2003P. lentimorbus semadara
Cry44AaBAD08532Ito et al2004Bt entomocidus INA288
Cry45AaBAD22577Okumura et al2004Bt 89-T-34-22
Cry46AaBAC79010Ito et al2004Bt dakota
Cry46Aa2BAG68906Ishikawa et al2008Bt A1470
Cry46AbBAD35170Yamagiwa et al2004Bt
Cry47AaAAY24695Kongsuwan et al2005Bt CAA890
Cry48AaCAJ18351Jones and Berry2005Bs IAB59binary with 49Aa
Cry48Aa2CAJ86545Jones and Berry2006Bs 47-6Bbinary with 49Aa2
Cry48Aa3CAJ86546Jones and Berry2006Bs NHA15bbinary with 49Aa3
Cry48AbCAJ86548Jones and Berry2006Bs LP1Gbinary with 49Ab1
Cry48Ab2CAJ86549Jones and Berry2006Bs 2173binary with 49Aa4
Cry49AaCAH56541Jones and Berry2005Bs IAB59binary with 48Aa
Cry49Aa2CAJ86541Jones and Berry2006Bs 47-6Bbinary with 48Aa2
Cry49Aa3CAJ86543Jones and Berry2006BsNHA15bbinary with 48Aa3
Cry49Aa4CAJ86544Jones and Berry2006Bs 2173binary with 48Ab2
Cry49Ab1CAJ86542Jones and Berry2006Bs LP1Gbinary with 48Ab1
Cry50Aa1BAE86999Ohgushi et al2006Bt sotto
Cry51Aa1ABI14444Meng et al2006Bt F14-1
Cry52Aa1EF613489Song et al2007Bt Y41No NCBI link July 2009
Cry52Ba1FJ361760Jun et al2008Bt BM59-2No NCBI link July 2009
Cry53Aa1EF633476Song et al2007Bt Y41No NCBI link July 2009
Cry53Ab1FJ361759Jun et al2008Bt MC28No NCBI link July 2009
Cry54Aa1ACA52194Tan et al2009Bt MC28
Cry55Aa1ABW88932Guo et al2008YBT 1518
Cry55Aa2AAE33526Bradfisch et al2000BT Y41
Cry56Aa1FJ597621Jun & Furong2008Bt Ywc2-8No NCBI link July 2009
Cry56Aa2GQ483512Guan Peng et al2009Bt G7-1No NCBI link August 2009
Cry57Aa1ANC87261Noguera & Ibarra2009Bt kim
Cry58Aa1ANC87260Noguera & Ibarra2009Bt entomocidus
Cry59Aa1ACR43758Noguera & Ibarra2009Bt kim LBIT-980
Vip3Aa1Vip3AaAAC37036Estruch et al1996PNAS 93,AB88
5389-5394
Vip3Aa2Vip3AbAAC37037Estruch et al1996PNAS 93,AB424
5389-5394
Vip3Aa3Vip3AcEstruch et al2000U.S. Pat. No.
6,137,033
October 2000
Vip3Aa4PS36A SupAAR81079Feitelson et al1998U.S. Pat. No.Bt PS36AWO9818932(A2, A3)
6,656,9087 May 1998
December 2003
Vip3Aa5PS81F SupAAR81080Feitelson et al1998U.S. Pat. No.Bt PS81FWO9818932(A2, A3)
6,656,9087 May 1998
December 2003
Vip3Aa6Jav90 SupAAR81081Feitelson et al1998U.S. Pat. No.BtWO9818932(A2, A3)
6,656,9087 May 1998
December 2003
Vip3Aa7Vip83AAK95326Cai et al2001unpublishedBt YBT-833
Vip3Aa8Vip3AAAK97481Loguercio et al2001unpublishedBt HD125
Vip3Aa9VipSCAA76665Selvapandiyan2001unpublishedBt A13
et al
Vip3Aa10Vip3VAAN60738Doss et al2002Protein Expr.Bt
Purif. 26, 82-88
Vip3Aa11Vip3AAAR36859Liu et al2003unpublishedBt C9
Vip3Aa12Vip3A-WB5AAM22456Wu and Guan2003unpublishedBt
Vip3Aa13Vip3AAAL69542Chen et al2002Sheng WuBt S184
Gong Cheng
Xue Bao 18,
687-692
Vip3Aa14VipAAQ12340Polumetla et al2003unpublishedBt tolworthi
Vip3Aa15Vip3AAAP51131Wu et al2004unpublishedBt WB50
Vip3Aa16Vip3LBAAW65132Mesrati et al2005FEMS MicroBt
Lett 244,
353-358
Vip3Aa17Jav90Feitelson et al1999U.S. Pat. No.Javelin 1990WO9957282(A2, A3)
6,603,06311 Nov. 1999
August 2003
Vip3Aa18AAX49395Cai and Xiao2005unpublishedBt 9816C
Vip3Aa19Vip3ALDDQ241674Liu et al2006unpublishedBt AL
Vip3Aa19Vip3A-1DQ539887Hart et al2006unpublished
Vip3Aa20Vip3A-2DQ539888Hart et al2006unpublished
Vip3Aa21VipABD84410Panbangred2006unpublishedBt aizawai
Vip3Aa22Vip3A-LS1AAY41427Lu et al2005unpublishedBt LS1
Vip3Aa23Vip3A-LS8AAY43428Lu et al2005unpublishedBt LS8
Vip3Aa24BI 880913Song et al2007unpublishedBt WZ-7
Vip3Aa25EF608501Hsieh et al2007unpublished
Vip3Aa26EU294496Shen and Guo2007unpublishedBt TF9
Vip3Aa27EU332167Shen and Guo2007unpublishedBt 16
Vip3Aa28FJ494817Xiumei Yu2008unpublishedBt JF23-8
Vip3Aa29FJ626674Xieumei et al2009unpublishedBt JF21-1
Vip3Aa30FJ626675Xieumei et al2009unpublishedMD2-1
Vip3Aa31FJ626676Xieumei et al2009unpublishedJF21-1
Vip3Aa32FJ626677Xieumei et al2009unpublishedMD2-1
..
Vip3Ab1Vip3BAAR40284Feitelson et al1999U.S. Pat. No.Bt KB59A4-6WO9957282(A2, A3)
6,603,06311 Nov. 1999
August 2003
Vip3Ab2Vip3DAAY88247Feng and Shen2006unpublishedBt
..
Vip3Ac1PS49CNarva et al.US application
20040128716
..
Vip3Ad1PS158C2Narva et al.US application
20040128716
Vip3Ad2ISP3BCAI43276Van Rie et al2005unpublishedBt
..
Vip3Ae1ISP3CCAI43277Van Rie et al2005unpublishedBt
..
Vip3Af1ISP3ACAI43275Van Rie et al2005unpublishedBt
Vip3Af2Vip3CADN08753Syngenta.WO 03/075655
..
Vip3Ag1Vip3BADN08758Syngenta.WO 02/078437
Vip3Ag2FJ556803Audtho et al2008Bt
..
Vip3Ah1Vip3SDQ832323Li and Shen2006unpublishedBt
.
Vip3Ba1AAV70653Rang et al2004unpublished
.
Vip3Bb1Vip3ZADN08760Syngenta.WO 03/075655
Vip3Bb2EF439819Akhurst et al2007

Claims as granted

19 claims

Log in to read the claims of this application.

Log in to unlock

Classifications

2 codes
IPC · International Patent Classification
Section A — Human necessities
  • A01N63/50
Section C — Chemistry; metallurgy
  • C12N15/82

Claim changes

Soon
Coming soonHow the claims changed between publication and grant

See which claims were amended, added or cancelled during examination, with every added and removed word marked.

AmendedAddedCancelledUnchanged

The published claims of this application are not paired with the granted ones in what we hold.

File wrapper

⤢ drag to zoomJan 2011Jul 2011Jan 2012Jul 2012Jan 2013Jul 2013Jan 2014Jul 2014Jan 2015Jul 2015USPTOApplicantNon-final rejectionResponse after non-final
USPTOApplicanthover for detail · click to open
Pendency
4.8 y
1,741 days filing → grant
Office actions
2
non-final + final
Responses
3
no RCE
Examiner
Anne Kubelik
art unit 1662 · TC 1600
Citations: 20 back · 4 forward

See the full prosecution history — every USPTO and applicant action on this file, in order.

Log in to unlock

Documents

Log in to open the documents of this file: the application as filed, every office action and response, the notice of allowance.

Log in to unlock

Chain of title

⤢ drag to zoom20162018202020222024202620282030Owner 1Owner 2
Titlehover for detail · click to open

See the full assignment history — every owner this patent has passed through, with recordation dates and reel/frame numbers.

Log in to unlock